{
    "questions": [
        {
            "documents": [],
            "snippets": [],
            "body": "Can Rozanolixizumab be used for treatment of multiple sclerosis?",
            "type": "yesno",
            "id": "65d1350f1930410b13000038",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [],
            "snippets": [],
            "body": "Are FOLFIRINOX plus Bevacizumab the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation?",
            "type": "yesno",
            "id": "65f77701c4010b4d78000030",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32861227",
                "http://www.ncbi.nlm.nih.gov/pubmed/28514310",
                "http://www.ncbi.nlm.nih.gov/pubmed/24076606",
                "http://www.ncbi.nlm.nih.gov/pubmed/35575803"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32861227",
                    "offsetInBeginSection": 361,
                    "offsetInEndSection": 480,
                    "text": "Plasma lactate at 0 h and 6 h was significantly higher, and lactate clearance was significantly lower in non-survivors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32861227",
                    "offsetInBeginSection": 481,
                    "offsetInEndSection": 604,
                    "text": "The optimal cut-off of plasma lactate at 6h for identifying mortality was 2.5 mmol/L (sensitivity 85% and specificity 74%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32861227",
                    "offsetInBeginSection": 605,
                    "offsetInEndSection": 817,
                    "text": "pSOFA score had the best predictive ability for mortality (AUC 0.89) followed by hs-CRP at 0 h (AUC 0.86), hs-CRP at 48 h (AUC 0.83), plasma lactate levels at 6 h (AUC 0.83), and plasma lactate at 0 h (AUC 0.67).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28514310",
                    "offsetInBeginSection": 903,
                    "offsetInEndSection": 1120,
                    "text": "According to the training group, 6 variables (brain natriuretic peptide, albumin, total bilirubin, D-dimer, lactate levels, and mechanical ventilation in 24 hours) were included in the final logistic regression model.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24076606",
                    "offsetInBeginSection": 1376,
                    "offsetInEndSection": 1499,
                    "text": "In our population of children with septic shock, SI was a clinically relevant and easily calculated predictor of mortality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35575803",
                    "offsetInBeginSection": 1040,
                    "offsetInEndSection": 1284,
                    "text": "In the subset with suspected infection, visit meeting criteria for sepsis (suspected infection with a pSOFA score of 2 or more) and septic shock (suspected infection with vasoactive infusion and serum lactate level >18.0 mg/dL) were identified.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can lactate levels predict mortality in paediatric sepsis?",
            "type": "yesno",
            "id": "660c44f7fdcbea915f000033",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38016166",
                "http://www.ncbi.nlm.nih.gov/pubmed/32769757",
                "http://www.ncbi.nlm.nih.gov/pubmed/31415087",
                "http://www.ncbi.nlm.nih.gov/pubmed/36924778",
                "http://www.ncbi.nlm.nih.gov/pubmed/37541194",
                "http://www.ncbi.nlm.nih.gov/pubmed/36470539",
                "http://www.ncbi.nlm.nih.gov/pubmed/37335635",
                "http://www.ncbi.nlm.nih.gov/pubmed/26653113",
                "http://www.ncbi.nlm.nih.gov/pubmed/37252752",
                "http://www.ncbi.nlm.nih.gov/pubmed/37990323"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38016166",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 225,
                    "text": "The neurokinin 3 receptor antagonist fezolinetant 45 mg/d significantly reduced frequency/severity of moderate to severe vasomotor symptoms (VMS) of menopause compared with placebo in two phase 3 randomized controlled trials.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32769757",
                    "offsetInBeginSection": 1762,
                    "offsetInEndSection": 1957,
                    "text": "Oral fezolinetant was associated with higher responder rates than placebo and larger improvements in QoL and other PRO measures, including a reduction in VMS-related interference with daily life.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31415087",
                    "offsetInBeginSection": 1581,
                    "offsetInEndSection": 1741,
                    "text": "Fezolinetant rapidly and significantly reduced moderate/severe VMSs, supporting its potential as an effective nonhormonal treatment option for menopausal women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36924778",
                    "offsetInBeginSection": 3289,
                    "offsetInEndSection": 3412,
                    "text": "Data support the clinical use of fezolinetant as a non-hormonal treatment for vasomotor symptoms associated with menopause.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36924778",
                    "offsetInBeginSection": 214,
                    "offsetInEndSection": 366,
                    "text": "Fezolinetant is one of the first non-hormonal neurokinin 3 receptor antagonists in development for the treatment of vasomotor symptoms due to menopause.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37541194",
                    "offsetInBeginSection": 165,
                    "offsetInEndSection": 352,
                    "text": "NK3 receptor antagonism has emerged as a novel therapeutic strategy, leading to the recent FDA approval of fezolinetant, a first-in-class nonhormonal treatment for menopausal hot flashes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32769757",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "In the primary analysis of the phase 2b VESTA study, oral fezolinetant reduced frequency and severity of menopausal vasomotor symptoms (VMS) compared with placebo.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36470539",
                    "offsetInBeginSection": 771,
                    "offsetInEndSection": 911,
                    "text": "Regarding non-HT, fezolinetant, currently in phase III clinical trials, is poised to become a first-in-class therapy for vasomotor symptoms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37335635",
                    "offsetInBeginSection": 841,
                    "offsetInEndSection": 998,
                    "text": "Moderately strong evidence was found suggesting that NK1/3 receptor antagonists can help limit the frequency and severity of hot flashes in menopausal women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26653113",
                    "offsetInBeginSection": 1686,
                    "offsetInEndSection": 1930,
                    "text": "Oral administration of the NK3R antagonist, ESN364, suppressed the hypothalamic-pituitary-gonadal axis in healthy volunteers by selective modulation of gonadotropin secretion, leading to a restrained decrease in ovarian hormone levels in women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the use of fezolinetant?",
            "type": "summary",
            "id": "65d136f41930410b1300003d",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20718710",
                "http://www.ncbi.nlm.nih.gov/pubmed/37597246",
                "http://www.ncbi.nlm.nih.gov/pubmed/35402275",
                "http://www.ncbi.nlm.nih.gov/pubmed/29140271",
                "http://www.ncbi.nlm.nih.gov/pubmed/26956206"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20718710",
                    "offsetInBeginSection": 1037,
                    "offsetInEndSection": 1197,
                    "text": "It is well established in CRC that mutations in KRAS are predictive of resistance to EGFR pathway inhibition, and may predict for a poorer outcome with therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37597246",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "text": "Activating RAS gene mutations occur in approximately 55% of patients with metastatic colorectal cancer (mCRC) and are associated with poorer clinical outcomes due to epidermal growth factor receptor (EGFR) blockade resistance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35402275",
                    "offsetInBeginSection": 1012,
                    "offsetInEndSection": 1126,
                    "text": "Seven genes in lung cancer and 16 genes in colorectal cancer were found, namely, APC, TP53, KRAS, SMAD4, and EGFR.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29140271",
                    "offsetInBeginSection": 505,
                    "offsetInEndSection": 604,
                    "text": "The resistance mechanisms to EGFR-targeted therapies can be categorized as resistant gene mutations",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26956206",
                    "offsetInBeginSection": 1159,
                    "offsetInEndSection": 1324,
                    "text": "We propose CSC lines as a sound preclinical framework to test the effects of therapies in vitro and in vivo and to identify novel determinants of therapy resistance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26956206",
                    "offsetInBeginSection": 1325,
                    "offsetInEndSection": 1456,
                    "text": "Colorectal cancer stem cells (CSCs) have been shown to be responsible for tumor propagation, metastatic dissemination, and relapse.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which gene mutations confer acquired resistance to anti-EGFR therapy in advance colorectal cancer?",
            "type": "list",
            "id": "65f7764fc4010b4d7800002f",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35558050",
                "http://www.ncbi.nlm.nih.gov/pubmed/35892582",
                "http://www.ncbi.nlm.nih.gov/pubmed/29154879",
                "http://www.ncbi.nlm.nih.gov/pubmed/29298722",
                "http://www.ncbi.nlm.nih.gov/pubmed/33023198",
                "http://www.ncbi.nlm.nih.gov/pubmed/32582833",
                "http://www.ncbi.nlm.nih.gov/pubmed/26959008",
                "http://www.ncbi.nlm.nih.gov/pubmed/29080524",
                "http://www.ncbi.nlm.nih.gov/pubmed/21547208",
                "http://www.ncbi.nlm.nih.gov/pubmed/37625763"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35558050",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "The onset of Alzheimer's disease (AD) is associated with the presence of neurofibrillary pathology such as amyloid  (A) plaques.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35892582",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "Amyloid- (A)-peptide production or deposition in the neuropathology of Alzheimer's disease (AD)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29154879",
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 224,
                    "text": "Excessive extra cellular deposits of amyloid beta (A) are a pathological feature of AD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29298722",
                    "offsetInBeginSection": 82,
                    "offsetInEndSection": 164,
                    "text": "Accumulation of amyloid- (A) in the brain is considered central in AD pathogenesis",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33023198",
                    "offsetInBeginSection": 278,
                    "offsetInEndSection": 420,
                    "text": "The cardinal features of AD include extracellular accumulation of amyloid  (A) and intracellular deposits of hyper-phosphorylated tau (p-tau).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33023198",
                    "offsetInBeginSection": 564,
                    "offsetInEndSection": 787,
                    "text": "The accumulation of A and iron in drusen, the hallmark of AMD, and A and p-tau in retinal ganglion cells (RGC), the main retinal cell type implicated in glaucoma, and accompanying inflammation suggest overlapping pathology.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32582833",
                    "offsetInBeginSection": 486,
                    "offsetInEndSection": 635,
                    "text": "CSF irisin correlated positively with BDNF, A Results indicate that CSF irisin and BDNF are directly correlated with A pathology and cognition in AD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26959008",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "text": "Amyloid- (A) pathology is known to promote chronic inflammatory responses in the brain.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29080524",
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 498,
                    "text": "Histopathological hallmarks of AD are intracellular neurofibrillary tangles and extracellular formation of senile plaques composed of the amyloid-beta peptide (A) in aggregated form along with metal-ions such as copper, iron or zinc.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21547208",
                    "offsetInBeginSection": 135,
                    "offsetInEndSection": 215,
                    "text": "Mitochondrial amyloid-beta (A) accumulation precedes extracellular A deposition.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Amyloid-Î² is associated with what diseases?",
            "type": "list",
            "id": "66097092fdcbea915f000010",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32067949",
                "http://www.ncbi.nlm.nih.gov/pubmed/20594913",
                "http://www.ncbi.nlm.nih.gov/pubmed/8973401",
                "http://www.ncbi.nlm.nih.gov/pubmed/11189709",
                "http://www.ncbi.nlm.nih.gov/pubmed/17434699",
                "http://www.ncbi.nlm.nih.gov/pubmed/14500917",
                "http://www.ncbi.nlm.nih.gov/pubmed/21761794",
                "http://www.ncbi.nlm.nih.gov/pubmed/8243594",
                "http://www.ncbi.nlm.nih.gov/pubmed/16402512",
                "http://www.ncbi.nlm.nih.gov/pubmed/1947808"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32067949",
                    "offsetInBeginSection": 1301,
                    "offsetInEndSection": 1430,
                    "text": "Of the 18 Ixodes species ticks evaluated to date, 13 were experimentally confirmed as vectors of B. burgdorferi s.l. spirochetes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20594913",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 234,
                    "text": "Lyme disease, or Lyme borreliosis, the most prevalent arthropod-borne disease in the Western world, is caused by spirochetes belonging to the Borrelia burgdorferi sensu lato group and is predominantly transmitted through Ixodes ticks.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8973401",
                    "offsetInBeginSection": 235,
                    "offsetInEndSection": 457,
                    "text": "Borrelia burgdorferi, the etiologic agent, is transmitted primarily by the western blacklegged tick (Ixodes pacificus) in far western North America, and by the blacklegged tick (Ixodes scapularis) in eastern North America.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11189709",
                    "offsetInBeginSection": 243,
                    "offsetInEndSection": 483,
                    "text": "In Europe, the vector of the disease is the tick Ixodes ricinus, whereas in the United States of America, two primary tick vectors exist, namely: I. scapularis in the north-eastern and mid-western regions and I. pacificus on the west coast.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17434699",
                    "offsetInBeginSection": 90,
                    "offsetInEndSection": 197,
                    "text": "Borrelia burgdorferi sensu lato causes Lyme disease and is transmitted by a tick belonging to Ixodes genus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14500917",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "text": "Lyme borreliosis, or Lyme disease (LD), is a tick-borne zoonotic infection of biomedical significance, caused by Borrelia burgdorferi sensu lato (s.l.) spirochetes and transmitted by Ixodes species ticks.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21761794",
                    "offsetInBeginSection": 238,
                    "offsetInEndSection": 343,
                    "text": "Lyme disease is caused by spirochetes of Borrelia burgdorferi sensu lato and transmitted by Ixodes ticks.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8243594",
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 290,
                    "text": "In this study, Ixodes ricinus ticks, the prevalent tick species in our country, are identified as the vectors of Borrelia burgdorferi in Slovenia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16402512",
                    "offsetInBeginSection": 297,
                    "offsetInEndSection": 542,
                    "text": "The geographic distribution of B. burgdorferi infections in equidae should resemble that of human cases because the vector tick involved, Ixodes ricinus, feeds on both species and, indeed, the infection has been established many times in horses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1947808",
                    "offsetInBeginSection": 214,
                    "offsetInEndSection": 373,
                    "text": "Two Eurasian (Ixodes ricinus and I. persulcatus) and three North American (I. dammini, I. scapularis and I. pacificus) species vector B. burgdorferi to humans.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which tick genus is the vector for Lyme disease?",
            "type": "factoid",
            "id": "660c0071fdcbea915f00002b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What is the mechanism of action of Zilebesiran?",
            "type": "summary",
            "id": "65cfd7981930410b13000022",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20533731",
                "http://www.ncbi.nlm.nih.gov/pubmed/20533129",
                "http://www.ncbi.nlm.nih.gov/pubmed/35221034",
                "http://www.ncbi.nlm.nih.gov/pubmed/21882994",
                "http://www.ncbi.nlm.nih.gov/pubmed/21670676",
                "http://www.ncbi.nlm.nih.gov/pubmed/32166917",
                "http://www.ncbi.nlm.nih.gov/pubmed/20105604",
                "http://www.ncbi.nlm.nih.gov/pubmed/35164831",
                "http://www.ncbi.nlm.nih.gov/pubmed/24726116",
                "http://www.ncbi.nlm.nih.gov/pubmed/11444757"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20533731",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Minimally invasive surgery (Nuss procedure) is being accepted rapidly as a preferred method for pectus excavatum repair.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20533731",
                    "offsetInBeginSection": 805,
                    "offsetInEndSection": 902,
                    "text": "The minimally invasive technique has evolved into an effective method of pectus excavatum repair.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20533129",
                    "offsetInBeginSection": 317,
                    "offsetInEndSection": 437,
                    "text": "A summary of the different approaches and techniques of pectus excavatum repair, bar insertion and removal is presented.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20533129",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Many technical variations have been introduced for the surgical correction of pectus excavatum (PE).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20533129",
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 570,
                    "text": "Various procedures, their advantages and disadvantages, the techniques employed and associated complications are discussed in depth.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35221034",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "Minimally invasive repair of pectus excavatum or the Nuss procedure has become the standard operation for pectus excavatum repair.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35221034",
                    "offsetInBeginSection": 228,
                    "offsetInEndSection": 521,
                    "text": "To optimize surgical outcomes of asymmetric pectus excavatum repair, previous work has proposed morphology-tailored bar shaping technique; the bar to be inserted is shaped asymmetrically to counter-balance the outer contour of the chest prior to the passage of the introducer across the chest.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21882994",
                    "offsetInBeginSection": 361,
                    "offsetInEndSection": 581,
                    "text": "Many papers suggest measures to prevent these complications: approaching the retrosternal space through an additional subxiphoid short incision, lifting the sternum during bar placement, or placing the bar extrapleuraly.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21670676",
                    "offsetInBeginSection": 1021,
                    "offsetInEndSection": 1191,
                    "text": "As a result of numerous technical improvements, safe and effective operative correction of pectus excavatum has been reported for both the Nuss procedure and open repair.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32166917",
                    "offsetInBeginSection": 1309,
                    "offsetInEndSection": 1471,
                    "text": "Bilateral thoracoscopic cryoanalgesia during minimally invasive pectus excavatum repair leads to early discharge and good postoperative pain control in all cases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "List the methods for pectus excavatum repair?",
            "type": "list",
            "id": "66080f4cfdcbea915f000004",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7474496",
                "http://www.ncbi.nlm.nih.gov/pubmed/21467938",
                "http://www.ncbi.nlm.nih.gov/pubmed/34998307",
                "http://www.ncbi.nlm.nih.gov/pubmed/12619374",
                "http://www.ncbi.nlm.nih.gov/pubmed/10348212",
                "http://www.ncbi.nlm.nih.gov/pubmed/29345235",
                "http://www.ncbi.nlm.nih.gov/pubmed/3963884",
                "http://www.ncbi.nlm.nih.gov/pubmed/1283757",
                "http://www.ncbi.nlm.nih.gov/pubmed/9072156",
                "http://www.ncbi.nlm.nih.gov/pubmed/35794604"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7474496",
                    "offsetInBeginSection": 1650,
                    "offsetInEndSection": 1800,
                    "text": "With the recent remarkable alleviation of air pollution, the consultation rate and mortality rate due to bronchial asthma have decreased considerably.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21467938",
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 309,
                    "text": "Outdoor air pollution has been associated with asthma exacerbations, including emergency department visits and hospitalizations, as well as with the onset of asthma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34998307",
                    "offsetInBeginSection": 448,
                    "offsetInEndSection": 652,
                    "text": "Air pollution causes significant morbidity and mortality in patients with inflammatory airway diseases such as allergic rhinitis, chronic rhinosinusitis, asthma, and chronic obstructive pulmonary disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12619374",
                    "offsetInBeginSection": 1802,
                    "offsetInEndSection": 1940,
                    "text": "In conclusion, air pollution is an important etiological factor for many chronic respiratory disorders, such as bronchial asthma and COPD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10348212",
                    "offsetInBeginSection": 276,
                    "offsetInEndSection": 576,
                    "text": "While smoking has been demonstrated to cause and aggravate COPD and bronchial asthma, the influence of air pollution, suspected to have hazardous environmental effects since the historical episodes of severe air pollution such as the London Smog, on the prevalence of airway diseases remains unclear.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29345235",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 352,
                    "text": "The rising frequency of obstructive respiratory diseases during recent years, in particular allergic asthma, can be partially explained by changes in the environment, with the increasing presence in the atmosphere of chemical triggers (particulate matter and gaseous components such as nitrogen dioxide and ozone) and biologic triggers (aeroallergens).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29345235",
                    "offsetInBeginSection": 777,
                    "offsetInEndSection": 989,
                    "text": "Urbanization and high levels of vehicle emissions induce symptoms of bronchial obstruction (in particular bronchial asthma), more so in people living in urban areas compared than in those who live in rural areas.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34998307",
                    "offsetInBeginSection": 653,
                    "offsetInEndSection": 839,
                    "text": "Oxidative stress in patients with respiratory diseases can induce eosinophilic inflammation in the airways, increase atopic allergic sensitization, and rise susceptibility to infections.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3963884",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 373,
                    "text": "In response to worsening air pollution, mortality for bronchial asthma and chronic bronchitis began to increase.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12619374",
                    "offsetInBeginSection": 1636,
                    "offsetInEndSection": 1801,
                    "text": "Moreover, air irritants can give rise to inflammatory damage of the mucous membrane of the airways, thereby making it more susceptible to various types of allergens.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Impact of pollution on asthma.",
            "type": "summary",
            "id": "660d27e3fdcbea915f000039",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35447317",
                "http://www.ncbi.nlm.nih.gov/pubmed/31455372",
                "http://www.ncbi.nlm.nih.gov/pubmed/21821313",
                "http://www.ncbi.nlm.nih.gov/pubmed/25670654",
                "http://www.ncbi.nlm.nih.gov/pubmed/24625603",
                "http://www.ncbi.nlm.nih.gov/pubmed/24921460",
                "http://www.ncbi.nlm.nih.gov/pubmed/23932292",
                "http://www.ncbi.nlm.nih.gov/pubmed/33553543",
                "http://www.ncbi.nlm.nih.gov/pubmed/32867801",
                "http://www.ncbi.nlm.nih.gov/pubmed/36553086"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35447317",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "text": "Culturing of deep tissues obtained at revision arthroplasty for Cutibacterium is a key component of diagnosing a periprosthetic infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31455372",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Synovial fluid -defensin is a valuable biomarker for periprosthetic joint infection (PJI).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21821313",
                    "offsetInBeginSection": 701,
                    "offsetInEndSection": 868,
                    "text": "Following knee arthroplasty, wound discharge was associated with an increased risk of prosthetic joint infection whereas the presence of a drain tube reduced the risk.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21821313",
                    "offsetInBeginSection": 869,
                    "offsetInEndSection": 1040,
                    "text": "By contrast, increased body mass index, increased drain tube loss and superficial incisional surgical site infections (SSIs) were associated with prosthetic hip infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25670654",
                    "offsetInBeginSection": 1720,
                    "offsetInEndSection": 1814,
                    "text": "Patients with a history of PJI had a greater risk of developing PJI in a subsequent THA or TKA",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24625603",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 283,
                    "text": "This study evaluated the usefulness of adding single-photon emission computed tomography (SPECT)/computed tomography (CT) (SPECT/CT) to technetium Tc 99m (Tc) hexamethylpropylene amine oxime (HMPAO)-labeled leukocyte imaging for diagnosing infections in hip or knee joint prostheses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24921460",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 259,
                    "text": "Through the use of polymerase chain reaction (PCR)-electron spray ionization (ESI)-time of flight (TOF)-mass spectrometry (MS), we identified multiple periodontal pathogens within joint tissues of individuals undergoing replacement arthroplasties of the knee.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23932292",
                    "offsetInBeginSection": 635,
                    "offsetInEndSection": 864,
                    "text": "Biomaterial-associated infections differ markedly for epidemiology, aetiology and severity, depending mainly on the anatomic site, on the time of biomaterial application, and on the depth of the tissues harbouring the prosthesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33553543",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "Contamination of the surgeon during gowning is a possible risk factor for prosthetic joint infection in arthroplasty surgery.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32867801",
                    "offsetInBeginSection": 1223,
                    "offsetInEndSection": 1345,
                    "text": "Seven cytokines showed infection-dependent increases in localized tissues: IL-1, IL-1, IL-6, IL-8, MCP-1, MIP-1, and MIP-1",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "In what part of the body would a periprosthetic infection occur?",
            "type": "factoid",
            "id": "66088ffafdcbea915f00000f",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17914311",
                "http://www.ncbi.nlm.nih.gov/pubmed/17530137",
                "http://www.ncbi.nlm.nih.gov/pubmed/20228689",
                "http://www.ncbi.nlm.nih.gov/pubmed/35307800",
                "http://www.ncbi.nlm.nih.gov/pubmed/26862508",
                "http://www.ncbi.nlm.nih.gov/pubmed/28375199"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17914311",
                    "offsetInBeginSection": 1415,
                    "offsetInEndSection": 1609,
                    "text": "Accordingly, pediatric critical care researchers have a responsibility to generate pediatric-specific evidence-based medicine for adjunctive corticosteroid therapy for severe sepsis in children.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17530137",
                    "offsetInBeginSection": 1562,
                    "offsetInEndSection": 1653,
                    "text": "Adjunctive therapy with stress dose of corticosteroid is indicated in selected populations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20228689",
                    "offsetInBeginSection": 1579,
                    "offsetInEndSection": 1721,
                    "text": "Children with severe sepsis who received adjunctive corticosteroid therapy exhibited similar illness severity compared with those who did not.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35307800",
                    "offsetInBeginSection": 940,
                    "offsetInEndSection": 1194,
                    "text": "Controversy remains regarding resuscitation fluid volume and type, antibiotic choices depending upon infectious risks in the patient's community, and adjunctive therapies such as vitamin C, corticosteroids, intravenous immunoglobulin, and methylene blue.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26862508",
                    "offsetInBeginSection": 689,
                    "offsetInEndSection": 876,
                    "text": "In group A, oral corticosteroids were used in 9 patients with a good response in 3 cases (no requiring other therapeutic option), the other patients required additional treatment options.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20228689",
                    "offsetInBeginSection": 1722,
                    "offsetInEndSection": 1873,
                    "text": "No definitive improvement in outcomes can be attributable to adjunctive corticosteroid therapy in the largest pediatric sepsis trial conducted to date.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28375199",
                    "offsetInBeginSection": 1260,
                    "offsetInEndSection": 1480,
                    "text": "All patients were treated with steroids and four needed additional treatment such as intravenous immunoglobulin in two patients, hydroxychloroquine and azathioprine in two and intravenous cyclophosphamide in one patient.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26862508",
                    "offsetInBeginSection": 877,
                    "offsetInEndSection": 921,
                    "text": "Cushing syndrome was observed in 3 patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26862508",
                    "offsetInBeginSection": 922,
                    "offsetInEndSection": 961,
                    "text": "One patient died of a fulminant sepsis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Should corticosteroids be considered as adjunctive therapy in paediatric sepsis management?",
            "type": "yesno",
            "id": "660c49f4fdcbea915f000034",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26396733",
                "http://www.ncbi.nlm.nih.gov/pubmed/15524419",
                "http://www.ncbi.nlm.nih.gov/pubmed/18073178",
                "http://www.ncbi.nlm.nih.gov/pubmed/11737240",
                "http://www.ncbi.nlm.nih.gov/pubmed/25379046",
                "http://www.ncbi.nlm.nih.gov/pubmed/18363001",
                "http://www.ncbi.nlm.nih.gov/pubmed/34920065",
                "http://www.ncbi.nlm.nih.gov/pubmed/26351925",
                "http://www.ncbi.nlm.nih.gov/pubmed/37489147",
                "http://www.ncbi.nlm.nih.gov/pubmed/29567889"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26396733",
                    "offsetInBeginSection": 1371,
                    "offsetInEndSection": 1494,
                    "text": "Procalcitonin is a sensitive, independent, and useful biomarker in comparison to CRP in early diagnosis of neonatal sepsis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15524419",
                    "offsetInBeginSection": 1225,
                    "offsetInEndSection": 1336,
                    "text": "Measurement of procalcitonin concentrations may be useful for early diagnosis of late onset sepsis in neonates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18073178",
                    "offsetInBeginSection": 409,
                    "offsetInEndSection": 562,
                    "text": "Serum PCT levels significantly increase in systemic bacterial infection, necrotizing enterocolitis, and during both early and late onset neonatal sepsis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18073178",
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 657,
                    "text": "By using a cut-off limit of 0,5 microg/L, the PCT positive likelihoud ratio was found of 12.5.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11737240",
                    "offsetInBeginSection": 1258,
                    "offsetInEndSection": 1348,
                    "text": "Compared with I : T and CRP, PCT appears to be a more sensitive marker of neonatal sepsis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18073178",
                    "offsetInBeginSection": 803,
                    "offsetInEndSection": 922,
                    "text": "PCT may be useful in assessing the severity of infection, following the progress of treatment, and predicting outcomes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25379046",
                    "offsetInBeginSection": 1546,
                    "offsetInEndSection": 1618,
                    "text": "PCT is a highly effective early diagnostic marker of neonatal infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18363001",
                    "offsetInBeginSection": 1047,
                    "offsetInEndSection": 1169,
                    "text": "The semi-quantitative PCT test kit is of moderate sensitivity but poor specificity for early diagnosis of neonatal sepsis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18363001",
                    "offsetInBeginSection": 743,
                    "offsetInEndSection": 944,
                    "text": "At a PCT cut-off level of greater than or equal to 2 ng/ml, the sensitivity of the PCT-Q kit in detecting neonatal sepsis at the onset of symptoms was 88.9 percent and its specificity was 65.2 percent.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34920065",
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 466,
                    "text": "Biomarkers such as C-reactive protein (CRP), procalcitonin (PCT), and serum amyloid A (SAA) can help in the detection of sepsis at early stages.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Do elevated levels of procalcitonin help in diagnosing paediatric sepsis?",
            "type": "yesno",
            "id": "660c3591fdcbea915f000031",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33197662"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33197662",
                    "offsetInBeginSection": 1447,
                    "offsetInEndSection": 1606,
                    "text": "The peppermint oil was significantly reduced the frequency of nausea, vomiting, retching and the severity of nausea in cancer patients undergoing chemotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the optimal antiemetic treatment for FOLFIRINOX chemotherapy?",
            "type": "factoid",
            "id": "65f7798dc4010b4d78000038",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37965360"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37965360",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191,
                    "text": "In 2016 diplomatic personnel serving in Havana, Cuba, began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Please list the symptoms of Havana syndrome",
            "type": "list",
            "id": "65f857b0c4010b4d7800004f",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21673876",
                "http://www.ncbi.nlm.nih.gov/pubmed/12950413",
                "http://www.ncbi.nlm.nih.gov/pubmed/18200660",
                "http://www.ncbi.nlm.nih.gov/pubmed/15663834",
                "http://www.ncbi.nlm.nih.gov/pubmed/9802447",
                "http://www.ncbi.nlm.nih.gov/pubmed/36059351",
                "http://www.ncbi.nlm.nih.gov/pubmed/11313305",
                "http://www.ncbi.nlm.nih.gov/pubmed/20117342",
                "http://www.ncbi.nlm.nih.gov/pubmed/31112753",
                "http://www.ncbi.nlm.nih.gov/pubmed/35371788"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21673876",
                    "offsetInBeginSection": 413,
                    "offsetInEndSection": 601,
                    "text": "Indeed, patients with IBD colitis are six times more likely to develop colorectal cancer than the general population and have a higher frequency of multiple synchronous colorectal cancers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12950413",
                    "offsetInBeginSection": 519,
                    "offsetInEndSection": 745,
                    "text": "The magnitude of CRC risk increases with early age at IBD diagnosis, longer duration of symptoms, and extent of the disease, with pancolitis having a more severe inflammation burden and risk of the dysplasia-carcinoma cascade.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18200660",
                    "offsetInBeginSection": 344,
                    "offsetInEndSection": 581,
                    "text": "Colon cancer risk in inflammatory bowel disease increases with longer duration of colitis, greater anatomic extent of colitis, the presence of primary sclerosing cholangitis, family history of CRC and degree of inflammation of the bowel.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21673876",
                    "offsetInBeginSection": 116,
                    "offsetInEndSection": 319,
                    "text": "Although IBD-associated colorectal cancer (IBD-CRC) accounts for only 1-2% of all cases of colorectal cancer, IBD with colon involvement is among the top three high-risk conditions for colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12950413",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 306,
                    "text": "Although colorectal cancer (CRC), complicating ulcerative colitis and Crohn's disease, only accounts for 1-2% of all cases of CRC in the general population, it is considered a serious complication of the disease and accounts for approximately 15% of all deaths in inflammatory bowel disease (IBD) patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15663834",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 255,
                    "text": "Patients with inflammatory bowel disease (IBD) are subject to increased risks for the development of colorectal cancer (CRC), risks that are attributed to the duration and anatomic extent of disease in patients with ulcerative colitis and Crohn's disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9802447",
                    "offsetInBeginSection": 106,
                    "offsetInEndSection": 299,
                    "text": "Some investigators suggest that patients with extensive colitis have a genetic predisposition to CRC and that long-standing inflammation is not of primary importance in the promotion of cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18200660",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "Patients with long-standing inflammatory bowel disease (IBD) have an increased risk of developing colorectal cancer (CRC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18200660",
                    "offsetInBeginSection": 123,
                    "offsetInEndSection": 343,
                    "text": "Many of the molecular alterations responsible for sporadic colorectal cancer, namely chromosomal instability, microsatellite instability, and hypermethylation, also play a role in colitis-associated colon carcinogenesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36059351",
                    "offsetInBeginSection": 1913,
                    "offsetInEndSection": 2035,
                    "text": "Patients with IBD who have non-cholestatic liver disease might have a higher risk for colon cancer, even at a younger age.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Why does inflammatory bowel disease predispose to colorectal cancer?",
            "type": "summary",
            "id": "65f77ac9c4010b4d7800003c",
            "ideal_answer": ""
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What disease was studied in the ANGEL-ASPECT trial?",
            "type": "summary",
            "id": "65d145651930410b13000042",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37199451",
                "http://www.ncbi.nlm.nih.gov/pubmed/36344361",
                "http://www.ncbi.nlm.nih.gov/pubmed/37212258",
                "http://www.ncbi.nlm.nih.gov/pubmed/33335092",
                "http://www.ncbi.nlm.nih.gov/pubmed/37590262",
                "http://www.ncbi.nlm.nih.gov/pubmed/33077299",
                "http://www.ncbi.nlm.nih.gov/pubmed/36197845",
                "http://www.ncbi.nlm.nih.gov/pubmed/34077301",
                "http://www.ncbi.nlm.nih.gov/pubmed/37514954",
                "http://www.ncbi.nlm.nih.gov/pubmed/36423066"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37199451",
                    "offsetInBeginSection": 237,
                    "offsetInEndSection": 355,
                    "text": "In 2019, the JYNNEOS vaccine was approved for subcutaneous administration (0.5 ml per dose) to prevent mpox infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36344361",
                    "offsetInBeginSection": 123,
                    "offsetInEndSection": 312,
                    "text": "JYNNEOS, a Modified Vaccinia Ankara (MVA)-based live, non-replicating vaccine, was recently approved for monkeypox prevention for adults at high risk of MPXV infection in the United States.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37212258",
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 476,
                    "text": "With the emergence of the recent MPXV outbreak, JYNNEOS vaccine has been proposed to individuals at high-risk of exposure.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33335092",
                    "offsetInBeginSection": 1341,
                    "offsetInEndSection": 1543,
                    "text": "Based on this immunobridging analysis, the EBOV GP-specific-binding antibody levels elicited by the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in humans will likely provide protection against EBOV disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37590262",
                    "offsetInBeginSection": 1308,
                    "offsetInEndSection": 1460,
                    "text": "Currently recommended JYNNEOS vaccination among all adults at risk for mpox should be encouraged, irrespective of childhood smallpox vaccination status.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37212258",
                    "offsetInBeginSection": 268,
                    "offsetInEndSection": 353,
                    "text": "vaccination with vaccinia virus gives approximatively 85% of protection against MPXV.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33077299",
                    "offsetInBeginSection": 545,
                    "offsetInEndSection": 788,
                    "text": "The MVA-BN-Filo vaccine is based on a live, highly attenuated poxviral vector incapable of replicating in human cells and encodes glycoproteins of Ebola virus Zaire, Sudan virus and Marburg virus and the nucleoprotein of the Thai Forest virus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37212258",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "Monkeypox virus (MPXV) is a zoonotic disease endemic in the rainforest countries of Central and West Africa.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36197845",
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 424,
                    "text": "Our purpose is to develop a multivalent vaccine regimen protecting against each of these filoviruses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34077301",
                    "offsetInBeginSection": 374,
                    "offsetInEndSection": 535,
                    "text": "The campaign aimed to vaccinate approximately 200,000 people from Rwanda's Rubavu and Rusizi districts with the two-dose vaccine regimen Ad26.ZEBOV, MVA-BN-Filo.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "JYNNEOS vaccine is protective against which diseases?",
            "type": "list",
            "id": "65cfdc561930410b13000026",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29279095"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29279095",
                    "offsetInBeginSection": 712,
                    "offsetInEndSection": 946,
                    "text": "Although data need to be interpreted with caution due to the absence of randomized trials stratified based on tumor location, patients with left-sided CRC seem to benefit more from anti-EGFR therapy than patients with right-sided CRC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Why is the clinical benefit of EGFR inhibitors different in right and left colorectal cancer?",
            "type": "summary",
            "id": "65f773cdc4010b4d78000026",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23499293",
                "http://www.ncbi.nlm.nih.gov/pubmed/28829120",
                "http://www.ncbi.nlm.nih.gov/pubmed/24548560"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23499293",
                    "offsetInBeginSection": 1255,
                    "offsetInEndSection": 1473,
                    "text": "Although these antibodies are being used for detecting and blocking of hemichannels in normal and tumor cells, they can also be potentially used for tissue-specific treatment and drug delivery in clinical applications.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829120",
                    "offsetInBeginSection": 763,
                    "offsetInEndSection": 975,
                    "text": "We demonstrate that these targeted Connectosomes selectively interact with cells that express a model receptor, promoting the selective delivery of the chemotherapeutic doxorubicin to this target cell population.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829120",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "text": "Gap junctions, transmembrane protein channels that directly connect the cytoplasm of neighboring cells and enable the exchange of molecules between cells, are a promising new frontier for therapeutic delivery.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24548560",
                    "offsetInBeginSection": 1046,
                    "offsetInEndSection": 1202,
                    "text": "This may lead to reduced tumour hypoxia, promote the survival of normal cells, and enable improved therapeutic delivery or more effective radiation therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24548560",
                    "offsetInBeginSection": 870,
                    "offsetInEndSection": 1045,
                    "text": "We apply this knowledge to tumour vessel biology, proposing that contrary to current opinion, these data suggest a need to protect, maintain and/or restore cancer vasculature.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can Connexin hemi channels be used for drug delivery?",
            "type": "yesno",
            "id": "660712a1fdcbea915f000003",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24636301"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24636301",
                    "offsetInBeginSection": 436,
                    "offsetInEndSection": 603,
                    "text": "Early studies with cattle were instrumental in the development of the use of Koch's tuberculin as an in vivo measure of cell-mediated immunity for diagnostic purposes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24636301",
                    "offsetInBeginSection": 604,
                    "offsetInEndSection": 738,
                    "text": "Calmette and Guerin demonstrated the efficacy of an attenuated M. bovis strain (BCG) in cattle prior to use of this vaccine in humans.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Pasteurization kills Mycobacterium tuberculosis from infected cattle.",
            "type": "yesno",
            "id": "660c02e1fdcbea915f00002c",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36167379",
                "http://www.ncbi.nlm.nih.gov/pubmed/33849498",
                "http://www.ncbi.nlm.nih.gov/pubmed/27006364",
                "http://www.ncbi.nlm.nih.gov/pubmed/37001969",
                "http://www.ncbi.nlm.nih.gov/pubmed/27696682",
                "http://www.ncbi.nlm.nih.gov/pubmed/37103680",
                "http://www.ncbi.nlm.nih.gov/pubmed/32932427",
                "http://www.ncbi.nlm.nih.gov/pubmed/24179284",
                "http://www.ncbi.nlm.nih.gov/pubmed/22703884",
                "http://www.ncbi.nlm.nih.gov/pubmed/35726467"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36167379",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 67,
                    "text": "Social determinants of health (SDoH) contribute to health outcomes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33849498",
                    "offsetInBeginSection": 123,
                    "offsetInEndSection": 347,
                    "text": "Recognizing the importance of the social determinants of health (SDOH), different actors in the health care, public health, and social service sectors are increasingly collaborating to improve health outcomes in communities.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27006364",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "Action on the social determinants of health (SDH) through intersectoral policymaking is often suggested to promote health and health equity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37001969",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "text": "Interventions to tackle the social determinants of health can improve outcomes during pregnancy and early childhood, leading to better health across the life course.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27696682",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "There is substantial evidence across different healthcare contexts that social determinants of health are strongly associated with morbidity and mortality in the United States.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37103680",
                    "offsetInBeginSection": 611,
                    "offsetInEndSection": 761,
                    "text": "These plans can shape the social determinants of health, such as housing, transportation, and green space, which significantly impact health outcomes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32932427",
                    "offsetInBeginSection": 1418,
                    "offsetInEndSection": 1576,
                    "text": "Social determinants of health are known to contribute to inequality in outcomes, though the impact on pediatric rare disease patients is not fully understood.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32932427",
                    "offsetInBeginSection": 1577,
                    "offsetInEndSection": 1670,
                    "text": "Diagnostic genetic testing is a powerful tool, though it may not be available to all in need.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24179284",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "text": "The social determinants of health (SDH) include factors apart from genes and biology that affect population health.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22703884",
                    "offsetInBeginSection": 856,
                    "offsetInEndSection": 1067,
                    "text": "The findings stress the importance of human drivers of vulnerability and adaptive capacity and the need to address social determinants of health in order to reduce the potential disease burden of climate change.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the estimated impact of social determinants of health on health outcomes?",
            "type": "factoid",
            "id": "65f86b3ac4010b4d78000058",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "TAK-994 is developed for which disease?",
            "type": "factoid",
            "id": "65cfd3961930410b1300001f",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "Is gout a very common inflammatory arthritis, which is caused by hyperbilirubinemia?",
            "type": "yesno",
            "id": "660d6cc3fdcbea915f00003d",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23254964",
                "http://www.ncbi.nlm.nih.gov/pubmed/21409384",
                "http://www.ncbi.nlm.nih.gov/pubmed/25536596",
                "http://www.ncbi.nlm.nih.gov/pubmed/24283603",
                "http://www.ncbi.nlm.nih.gov/pubmed/18471041",
                "http://www.ncbi.nlm.nih.gov/pubmed/24153157",
                "http://www.ncbi.nlm.nih.gov/pubmed/27843607",
                "http://www.ncbi.nlm.nih.gov/pubmed/25617075",
                "http://www.ncbi.nlm.nih.gov/pubmed/22044939",
                "http://www.ncbi.nlm.nih.gov/pubmed/22531628"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23254964",
                    "offsetInBeginSection": 1009,
                    "offsetInEndSection": 1121,
                    "text": "Bevacizumab-related HTN may represent a biomarker for clinical benefit in metastatic colorectal cancer patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21409384",
                    "offsetInBeginSection": 1648,
                    "offsetInEndSection": 1831,
                    "text": "Our data suggest that bevacizumab-related arterial hypertension may represent a predictive factor of response and prolonged PFS in patients with mCRC receiving first-line bevacizumab.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25536596",
                    "offsetInBeginSection": 1215,
                    "offsetInEndSection": 1420,
                    "text": "Bevacizumab-related hypertension was associated with increased ORR (RR= 1.63; 95% CI 1.26-2.12; p=0.0002), improved PFS (HR=0.68; 95% CI 0.58-0.79; p<0.00001) and OS (HR=0.52; 95% CI 0.42-0.66; p<0.00001).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24283603",
                    "offsetInBeginSection": 1239,
                    "offsetInEndSection": 1530,
                    "text": "The occurrence of bevacizumab-induced hypertension in patients was highly associated with improvements in PFS (HR = 0.57, 95% CI: 0.46-0.72; P <0.001), OS (HR = 0.50; 95% CI: 0.37-0.68; P <0.001), and ORR (RR = 1.57, 95% CI: 1.07-2.30, P <0.05), as compared to patients without hypertension.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23254964",
                    "offsetInBeginSection": 818,
                    "offsetInEndSection": 1008,
                    "text": "HTN was associated with better OS in HTN-positive versus HTN-negative patients (median not reached vs. 36.8 months, p = 0.029) and better PFS (29.9 vs. 17.2 months, p = 0.024, respectively).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18471041",
                    "offsetInBeginSection": 642,
                    "offsetInEndSection": 781,
                    "text": "The major adverse events associated with bevacizumab include grade III hypertension, bleeding and the risk of gastrointestinal perforation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24153157",
                    "offsetInBeginSection": 700,
                    "offsetInEndSection": 818,
                    "text": "Response rates were 42% for patients with grades 0 to 1 HTN compared with 86% for patients with grade 2 HTN (P=0.043).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843607",
                    "offsetInBeginSection": 181,
                    "offsetInEndSection": 399,
                    "text": "Hypertension (HTN) is a common complication of the treatment with bevacizumab and, owing to its close relation with antiangiogenic mechanism, may represent a clinical biomarker to predict the efficacy of the treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25617075",
                    "offsetInBeginSection": 1322,
                    "offsetInEndSection": 1511,
                    "text": "In this retrospective study, the rs3025039 polymorphism was significantly associated with time to treatment failure and hypertension in patients treated with bevacizumab-based chemotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044939",
                    "offsetInBeginSection": 952,
                    "offsetInEndSection": 1058,
                    "text": "Grade 2 hypertension was also an independent prognostic factor of longer progression-free survival and OS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is high blood pressure a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients?",
            "type": "yesno",
            "id": "66099b20fdcbea915f000021",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37366315",
                "http://www.ncbi.nlm.nih.gov/pubmed/37385280",
                "http://www.ncbi.nlm.nih.gov/pubmed/37865924",
                "http://www.ncbi.nlm.nih.gov/pubmed/10359479",
                "http://www.ncbi.nlm.nih.gov/pubmed/36048812"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37366315",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "text": "Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37385280",
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 284,
                    "text": "Retatrutide, a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon receptors",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37865924",
                    "offsetInBeginSection": 618,
                    "offsetInEndSection": 751,
                    "text": "briefly touches data on the efficacy and safety of the first triple receptor agonist drug, retatrutide, in preclinical human studies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37865924",
                    "offsetInBeginSection": 346,
                    "offsetInEndSection": 554,
                    "text": "the article reviews the other important physiological tasks of glucagon, especially its participation in intrainsular paracrine regulation, energy expenditure and the shaping of appetite and food consumption.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10359479",
                    "offsetInBeginSection": 456,
                    "offsetInEndSection": 691,
                    "text": "Here, we investigated the effects of the 5-HT1A receptor partial agonist ipsapirone, which produces behavioral effects and HPA-axis activation, to further characterize the 5-HT receptor subtype-specificity of these disturbances in SAD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36048812",
                    "offsetInBeginSection": 652,
                    "offsetInEndSection": 791,
                    "text": "We investigated the hypnotic drugs as follows; benzodiazepine drugs, Z-drugs, melatonin receptor agonists, and orexin receptor antagonists.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What receptors are targeted by Retatrutide?",
            "type": "list",
            "id": "65cfce461930410b1300001a",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37933195",
                "http://www.ncbi.nlm.nih.gov/pubmed/21258200",
                "http://www.ncbi.nlm.nih.gov/pubmed/33887991",
                "http://www.ncbi.nlm.nih.gov/pubmed/37210302",
                "http://www.ncbi.nlm.nih.gov/pubmed/31954635",
                "http://www.ncbi.nlm.nih.gov/pubmed/24152951",
                "http://www.ncbi.nlm.nih.gov/pubmed/22081920",
                "http://www.ncbi.nlm.nih.gov/pubmed/37405042",
                "http://www.ncbi.nlm.nih.gov/pubmed/29441227",
                "http://www.ncbi.nlm.nih.gov/pubmed/30363191"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37933195",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 241,
                    "text": "Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) is an important sequela complication of acute pancreatitis, which may cause poor prognosis, such as severe gastrointestinal hemorrhage, bowel ischemic necrosis and liver failure.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21258200",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "text": "Acute pancreatitis can result in many vascular complications in both artery and vein.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33887991",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Splanchnic vein thrombosis (SVT) is a serious vascular complication that can occur in patients with acute pancreatitis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37210302",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "Splanchnic vein thrombosis (SVT) is a well-recognised though little-studied complication in acute pancreatitis (AP).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37210302",
                    "offsetInBeginSection": 1163,
                    "offsetInEndSection": 1244,
                    "text": "This study identifies the risk factors and negative clinical impact of SVT in AP.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31954635",
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 288,
                    "text": "A consequence of severe acute pancreatitis is thrombus in the splanchnic veins. These thrombi can potentially lead to bowel ischemia or hepatic failure.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37933195",
                    "offsetInBeginSection": 340,
                    "offsetInEndSection": 553,
                    "text": "In this study, we reviewed the latest academic publications in APISVT, and discussed its pathogenesis, clinical presentation, adverse outcome and treatment, especially focused on the role of anticoagulant therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24152951",
                    "offsetInBeginSection": 1065,
                    "offsetInEndSection": 1136,
                    "text": "The use of AC was reasonably safe with no fatal bleeding complications.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21258200",
                    "offsetInBeginSection": 86,
                    "offsetInEndSection": 239,
                    "text": "Venous complication usually occurs as a form of splenic or portal vein thrombosis, and also can simultaneously occur in superior mesenteric vein as well.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21258200",
                    "offsetInBeginSection": 326,
                    "offsetInEndSection": 490,
                    "text": "Although it is uncommon, mesenteric vein thrombosis is an important clinical entity because of the possibility of mesenteric ischemia and infarction of small bowel.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the significance of Acute pancreatitis-induced splanchnic vein thrombosis",
            "type": "summary",
            "id": "66088cccfdcbea915f00000b",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15624766",
                "http://www.ncbi.nlm.nih.gov/pubmed/33650401",
                "http://www.ncbi.nlm.nih.gov/pubmed/36745176",
                "http://www.ncbi.nlm.nih.gov/pubmed/3964925",
                "http://www.ncbi.nlm.nih.gov/pubmed/27493372",
                "http://www.ncbi.nlm.nih.gov/pubmed/19501692",
                "http://www.ncbi.nlm.nih.gov/pubmed/11195957",
                "http://www.ncbi.nlm.nih.gov/pubmed/36962822",
                "http://www.ncbi.nlm.nih.gov/pubmed/37629614",
                "http://www.ncbi.nlm.nih.gov/pubmed/24520756"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15624766",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "Survivors of very premature birth face an increased risk of adverse motor, cognitive, and behavior sequelae.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33650401",
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 791,
                    "text": "Those born 34 to 36 weeks' gestation also have higher rates of short-term morbid premature birth-related conditions such as respiratory distress syndrome (RDS) and intraventricular hemorrhage (IVH) than their peers born at term.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36745176",
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 756,
                    "text": "premature birth itself, correlate with a higher risk for neurodevelopmental disabilities.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36745176",
                    "offsetInBeginSection": 268,
                    "offsetInEndSection": 366,
                    "text": "those delivered at less than 28 weeks gestation have the highest rates of morbidity and mortality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36745176",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 70,
                    "text": "Preterm birth affects 1 in every 10 infants born in the United States.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15624766",
                    "offsetInBeginSection": 701,
                    "offsetInEndSection": 937,
                    "text": "The premature baboons undergoing neonatal intensive care sustained a spectrum of neuropathologies including white matter injury, hemorrhage, and ventriculomegaly, which resemble lesions frequently observed in the human premature infant.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3964925",
                    "offsetInBeginSection": 380,
                    "offsetInEndSection": 574,
                    "text": "Renal calculi in neonates are complications of distinct, treatable conditions, and premature babies receiving furosemide treatment should be screened by ultrasonography for renal calcifications.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493372",
                    "offsetInBeginSection": 1057,
                    "offsetInEndSection": 1223,
                    "text": "Morbidity among the pre-term birth population showed that respiratory distress syndrome was the main disease accounting for 36% and 46.2% of the deaths, respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493372",
                    "offsetInBeginSection": 1224,
                    "offsetInEndSection": 1342,
                    "text": "Neonatal jaundice, apnoea, and neonatal infection occurred in 46%, 16% and 14% of the premature infants, respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19501692",
                    "offsetInBeginSection": 389,
                    "offsetInEndSection": 752,
                    "text": "They have increased mortality when compared to term infants and are at increased risk for complications including transient tachypnea of newborn (TTN), respiratory distress syndrome (RDS), persistent pulmonary hypertension (PPHN), respiratory failure, temperature instability, jaundice, feeding difficulties and prolonged neonatal intensive care unit (NICU) stay.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are common complications of prematurity for babies?",
            "type": "list",
            "id": "660c0a85fdcbea915f000030",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37029611",
                "http://www.ncbi.nlm.nih.gov/pubmed/31344431",
                "http://www.ncbi.nlm.nih.gov/pubmed/31533218",
                "http://www.ncbi.nlm.nih.gov/pubmed/31316514",
                "http://www.ncbi.nlm.nih.gov/pubmed/37937304",
                "http://www.ncbi.nlm.nih.gov/pubmed/37593337",
                "http://www.ncbi.nlm.nih.gov/pubmed/33317795",
                "http://www.ncbi.nlm.nih.gov/pubmed/35933808",
                "http://www.ncbi.nlm.nih.gov/pubmed/32739479",
                "http://www.ncbi.nlm.nih.gov/pubmed/36212852"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37029611",
                    "offsetInBeginSection": 765,
                    "offsetInEndSection": 965,
                    "text": "Examination of various clinical and experimental drugs by EM reveales that the gut microbiota affects drug efficacy through three pathways: immunological effects, bioaccumulation, and drug metabolism.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31344431",
                    "offsetInBeginSection": 456,
                    "offsetInEndSection": 528,
                    "text": "Gut microbiota can modulate the metabolism of drugs in a number of ways.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31344431",
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 743,
                    "text": "The presence of bacteria within the tumor environment can also impact the responses to cancer therapies; changing the chemical structure of chemotherapeutic drugs, affecting their activity, and local concentration.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31533218",
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 480,
                    "text": "Intestinal microbiome has been shown to participate in the resistance to a wide range of anticancer treatments by direct interaction with the treatment or by indirectly stimulating host response through immunomodulation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31316514",
                    "offsetInBeginSection": 770,
                    "offsetInEndSection": 942,
                    "text": "Furthermore, some of the taxa that are depleted in subjects with HIV have proved to modulate the anti-tumor efficacy of various chemotherapies and immunotherapeutic agents.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37937304",
                    "offsetInBeginSection": 114,
                    "offsetInEndSection": 224,
                    "text": "Microbiota modulates critical aspects of tumor biology including cell proliferation, invasion, and metastasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37937304",
                    "offsetInBeginSection": 480,
                    "offsetInEndSection": 642,
                    "text": "These microbiota-mediated effects significantly impact overall survival and the recurrence of tumors after surgery by affecting the efficacy of chemoradiotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37593337",
                    "offsetInBeginSection": 562,
                    "offsetInEndSection": 850,
                    "text": "Chemotherapy effectiveness, for example, appears to be strongly influenced by the presence of some microorganisms capable of modulating the pharmacokinetics and pharmacodynamics of the compounds used, thus varying the real response and therefore the efficacy of the oncological treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33317795",
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 332,
                    "text": "Current evidence suggests that alterations in the composition of the microbiota may affect efficacy and toxicity of anti-cancer therapies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33317795",
                    "offsetInBeginSection": 540,
                    "offsetInEndSection": 803,
                    "text": "This paper reviews effects of altered microbiome on anti-cancer management, including antibiotics, chemotherapy and immunotherapy, as well as possible outcomes of modulating altered microbiome by probiotics or faecal microbiome transplantation in cancer patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the mechanism by which the microbiota module the effectiveness of chemotherapy?",
            "type": "summary",
            "id": "65f77919c4010b4d78000036",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31437130",
                "http://www.ncbi.nlm.nih.gov/pubmed/37846131",
                "http://www.ncbi.nlm.nih.gov/pubmed/32606740",
                "http://www.ncbi.nlm.nih.gov/pubmed/30621282",
                "http://www.ncbi.nlm.nih.gov/pubmed/32336422",
                "http://www.ncbi.nlm.nih.gov/pubmed/31018069",
                "http://www.ncbi.nlm.nih.gov/pubmed/37156483",
                "http://www.ncbi.nlm.nih.gov/pubmed/30859413",
                "http://www.ncbi.nlm.nih.gov/pubmed/31548341",
                "http://www.ncbi.nlm.nih.gov/pubmed/32722779"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31437130",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 310,
                    "text": "Tagraxofusp (SL-401) is a CD123-targeted therapy consisting of interleukin-3 fused to a truncated diphtheria toxin payload.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37846131",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "Tagraxofusp (or SL-401) is a recombinant molecule composed of human interleukin-3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32606740",
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 378,
                    "text": "Tagraxofusp (or SL-401) is a recombinant cytotoxin which consists of human interleukin-3 fused to a truncated diphtheria toxin.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30621282",
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 739,
                    "text": "A genetically engineered diphtheria toxin fused with interleukin-3 (SL-401 or tagraxofusp) has shown robust activity in blastic plasmacytoid dendritic cell neoplasm and promising response rates in different myeloid malignancies, including eradication of minimal residual disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32336422",
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 204,
                    "text": "Tagraxofusp (SL-401) was the first drug approved specifically for patients with BPDCN, in 2018.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31018069",
                    "offsetInBeginSection": 220,
                    "offsetInEndSection": 341,
                    "text": "Tagraxofusp (SL-401) is a CD123-directed cytotoxin consisting of human interleukin-3 fused to truncated diphtheria toxin.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37156483",
                    "offsetInBeginSection": 1178,
                    "offsetInEndSection": 1420,
                    "text": "Tagraxofusp (SL-401), a recombinant fusion protein containing interleukin-3 fused to truncated diphtheria toxin, was the first approved CD123-targeted therapy for BPDCN based on a phase I/II clinical trial showing a 90% overall response rate.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30859413",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 301,
                    "text": "Tagraxofusp (tagraxofusp-erzs) [ElzonrisTM] is an intravenously administered CD123-directed cytotoxin (composed of human interleukin-3 and a truncated diphtheria toxin payload) that was developed by Stemline Therapeutics, Inc. for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30859413",
                    "offsetInBeginSection": 302,
                    "offsetInEndSection": 465,
                    "text": "In December 2018, tagraxofusp received its first global approval in the USA for the treatment of BPDCN in adults and in paediatric patients aged 2 years and older.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31548341",
                    "offsetInBeginSection": 112,
                    "offsetInEndSection": 267,
                    "text": "FDA approved tagraxofusp-erzs for the treatment of blastic plasmacytoid dendritic cell neoplasms (BPDCN) in adult and pediatric patients 2 years and older.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is Tagraxofusp?",
            "type": "summary",
            "id": "660a8fc4fdcbea915f000027",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34103404",
                "http://www.ncbi.nlm.nih.gov/pubmed/35338549",
                "http://www.ncbi.nlm.nih.gov/pubmed/34268531",
                "http://www.ncbi.nlm.nih.gov/pubmed/35973578",
                "http://www.ncbi.nlm.nih.gov/pubmed/37853604",
                "http://www.ncbi.nlm.nih.gov/pubmed/34699951",
                "http://www.ncbi.nlm.nih.gov/pubmed/36396025",
                "http://www.ncbi.nlm.nih.gov/pubmed/36529664",
                "http://www.ncbi.nlm.nih.gov/pubmed/37943548",
                "http://www.ncbi.nlm.nih.gov/pubmed/34873866"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34103404",
                    "offsetInBeginSection": 1074,
                    "offsetInEndSection": 1240,
                    "text": "Of those, the entry-inhibitor bulevirtide (formerly known as myrcludex B) received conditional marketing authorisation in the European Union (EU) in 2020 (Hepcludex).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35338549",
                    "offsetInBeginSection": 1307,
                    "offsetInEndSection": 1384,
                    "text": "Bulevirtide was included as a treatment option for the hepatitis Delta virus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34268531",
                    "offsetInBeginSection": 808,
                    "offsetInEndSection": 1045,
                    "text": "In July 2020 bulevirtide was authorized for use in the E.U. following a positive opinion by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in HDV RNA-positive adult patients with compensated liver disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35973578",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Bulevirtide (BLV) has recently been conditionally approved for the treatment of chronic hepatitis delta (CHD) in Europe",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37853604",
                    "offsetInBeginSection": 176,
                    "offsetInEndSection": 367,
                    "text": "Bulevirtide is a recently introduced entry inhibitor drug that acts on the sodium taurocholate cotransporting peptide, thereby preventing viral entry to target cells in chronic HDV infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34699951",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "text": "The entry inhibitor bulevirtide (BLV) received conditional approval from the EMA in July 2020 for the treatment of adult patients with compensated chronic hepatitis delta.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36396025",
                    "offsetInBeginSection": 601,
                    "offsetInEndSection": 780,
                    "text": "Bulevirtide, an entry inhibitor, was conditionally approved in July 2020 in the European Union for adult patients with chronic hepatitis delta (CHD) and compensated liver disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36529664",
                    "offsetInBeginSection": 737,
                    "offsetInEndSection": 880,
                    "text": "Limited treatments are available for HDV, but promise has been shown with the newly approved Bulevirtide, a first-in-class HBV entry inhibitor.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37943548",
                    "offsetInBeginSection": 1727,
                    "offsetInEndSection": 2052,
                    "text": "Phase 3 randomized clinical trials of bulevirtide, which blocks entry of HDV into hepatocytes, and lonafarnib, which interferes with HDV assembly, showed that compared with placebo or observation, these therapies attained virological and biochemical response in up to 56% of patients after 96 weeks of bulevirtide monotherapy",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34873866",
                    "offsetInBeginSection": 1477,
                    "offsetInEndSection": 1602,
                    "text": "Treatment with the sodium-taurocholate cotransporting polypeptide inhibitor bulevirtide was initiated in 20 (27.0%) patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What disease can be treatment with Bulevirtide?",
            "type": "factoid",
            "id": "65cfdaae1930410b13000025",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15668471",
                "http://www.ncbi.nlm.nih.gov/pubmed/1292765",
                "http://www.ncbi.nlm.nih.gov/pubmed/16630739",
                "http://www.ncbi.nlm.nih.gov/pubmed/14648970",
                "http://www.ncbi.nlm.nih.gov/pubmed/19584580",
                "http://www.ncbi.nlm.nih.gov/pubmed/7942610",
                "http://www.ncbi.nlm.nih.gov/pubmed/24535709",
                "http://www.ncbi.nlm.nih.gov/pubmed/21472195",
                "http://www.ncbi.nlm.nih.gov/pubmed/16079314",
                "http://www.ncbi.nlm.nih.gov/pubmed/36878228"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15668471",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 99,
                    "text": "Breast cancer in men is a rare disease, accounting for approximately 1% of all breast cancer cases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15668471",
                    "offsetInBeginSection": 393,
                    "offsetInEndSection": 494,
                    "text": "Overall, the epidemiology of MBC presents similarities with the epidemiology of female breast cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1292765",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Incidence data for male breast cancer from 34 selected cancer registries in different parts of the world are presented.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1292765",
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 442,
                    "text": "The geographic variation in incidence is similar to that observed for female breast cancer, resulting in a strong correlation between their respective rates, although certain populations have higher rates for male breast cancer than expected from the female incidence, notably Israeli Jews and blacks in the United States.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16630739",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "text": "Male breast cancer is an uncommon disease although its incidence has increased over the recent years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16630739",
                    "offsetInBeginSection": 401,
                    "offsetInEndSection": 534,
                    "text": "A database must be started with epidemiologic information to understand this disease and its correlation with breast cancer in women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14648970",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "Male breast cancer (MBC) is a rare disease, accounting for less than 1% of all breast cancers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14648970",
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 589,
                    "text": "This uncommon malignancy is most commonly seen in men over sixty years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19584580",
                    "offsetInBeginSection": 1111,
                    "offsetInEndSection": 1240,
                    "text": "An incidence of 4.1% for male breast cancer indicates that this disease is not as uncommon as presumed in this part of the world.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7942610",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "Breast cancer in men is a rare condition affecting only 1,000 men each year in the United States.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the epidemiology of breast cancer in men?",
            "type": "summary",
            "id": "660d6f0cfdcbea915f00003e",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35304396",
                "http://www.ncbi.nlm.nih.gov/pubmed/37082450",
                "http://www.ncbi.nlm.nih.gov/pubmed/30006431",
                "http://www.ncbi.nlm.nih.gov/pubmed/31150315",
                "http://www.ncbi.nlm.nih.gov/pubmed/31318794",
                "http://www.ncbi.nlm.nih.gov/pubmed/37697712",
                "http://www.ncbi.nlm.nih.gov/pubmed/37798027"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35304396",
                    "offsetInBeginSection": 986,
                    "offsetInEndSection": 1299,
                    "text": "Patients will be randomised to either arm A consisting of CRT (50.4 Gy with capecitabine) followed by consolidation chemotherapy (six cycles of CapeOx), or arm B consisting of induction chemotherapy (three cycles of CapeOx plus bevacizumab) followed by CRT and consolidation chemotherapy (three cycles of CapeOx).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37082450",
                    "offsetInBeginSection": 561,
                    "offsetInEndSection": 712,
                    "text": "Patients received three cycles of induction oxaliplatin and capecitabine (CapeOX) followed by chemoradiotherapy and two cycles of consolidation CapeOX.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30006431",
                    "offsetInBeginSection": 738,
                    "offsetInEndSection": 919,
                    "text": "total neoadjuvant therapy with induction chemotherapy followed by chemoradiotherapy to improve pCR and reduce the difficulty of delivering chemotherapy in the postoperative setting.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31150315",
                    "offsetInBeginSection": 434,
                    "offsetInEndSection": 695,
                    "text": "Patients with stage II or III rectal cancer were assigned to group A for induction chemotherapy using three cycles of fluorouracil, leucovorin, and oxaliplatin before fluorouracil/oxaliplatin CRT (50.4 Gy) or to group B for consolidation chemotherapy after CRT.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31318794",
                    "offsetInBeginSection": 397,
                    "offsetInEndSection": 540,
                    "text": "TNT was defined as chemotherapy using cycles of induction and/or consolidation in conjunction with standard chemoradiotherapy prior to surgery.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37697712",
                    "offsetInBeginSection": 1345,
                    "offsetInEndSection": 1440,
                    "text": "Neoadjuvant FOLFIRINOX has established efficacy, with a significant increase in the 3-year DFS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37798027",
                    "offsetInBeginSection": 295,
                    "offsetInEndSection": 377,
                    "text": "CRT combined with intra-arterial chemotherapy (IAC) might be a promising approach.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37798027",
                    "offsetInBeginSection": 538,
                    "offsetInEndSection": 693,
                    "text": "We assess whether IAC plus CRT and FOLFIRINOX consolidation chemotherapy can improve the chance of organ preservation and survival in distal rectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which initial chemotherapy regimen is the most appropriate in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients?",
            "type": "factoid",
            "id": "65f7785dc4010b4d78000033",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "Is Trifluridine/Tipiracil a preferential treatment over Regorafenib in elderly colorectal cancer patients?",
            "type": "yesno",
            "id": "65f7778fc4010b4d78000031",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34912592",
                "http://www.ncbi.nlm.nih.gov/pubmed/37850841",
                "http://www.ncbi.nlm.nih.gov/pubmed/35911695",
                "http://www.ncbi.nlm.nih.gov/pubmed/37473857",
                "http://www.ncbi.nlm.nih.gov/pubmed/36828830",
                "http://www.ncbi.nlm.nih.gov/pubmed/33344921",
                "http://www.ncbi.nlm.nih.gov/pubmed/37901238",
                "http://www.ncbi.nlm.nih.gov/pubmed/36765735",
                "http://www.ncbi.nlm.nih.gov/pubmed/34996812",
                "http://www.ncbi.nlm.nih.gov/pubmed/29924794"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34912592",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "text": "In cancer patients, the clinical response to checkpoint-based immunotherapy is associated with the composition and functional quality of the host microbiome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37850841",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "The microbiome affects cancer, from carcinogenesis to response to treatments.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35911695",
                    "offsetInBeginSection": 353,
                    "offsetInEndSection": 561,
                    "text": "TM plays an important role in the formation of the tumor microenvironment, regulation of local immunity, and modification of tumor cell biology, and directly affects the efficacy of drug treatment for tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37473857",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "The microbiota is garnering progressively greater consideration as an essential facet of the tumor microenvironment that regulates tumor proliferation and affects cancer prognosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37473857",
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 747,
                    "text": "Mechanistic studies have revealed that the tumor-associated microbiota contributes to playing a pivotal role in the establishment of the tumor microenvironment, regulation of local immunity, modulation of tumor cell biology, and directly influences the therapeutic efficacy of drug treatment for tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34912592",
                    "offsetInBeginSection": 1052,
                    "offsetInEndSection": 1194,
                    "text": "Our study suggests novel microbiome-specific/derived biomarkers for checkpoint immunotherapy response prediction and prognosis in lung cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36828830",
                    "offsetInBeginSection": 125,
                    "offsetInEndSection": 390,
                    "text": "Increasing evidence has put a spotlight on the connection of microbiota to T cells, by showing impaired effector and/or memory responses in germ-free (GF) mice or in the presence of dysbiotic communities, and association with tumor growth and overall survival (OS).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33344921",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "text": "Recent studies have begun to highlight the diverse and tumor-specific microbiomes across multiple cancer types.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37850841",
                    "offsetInBeginSection": 78,
                    "offsetInEndSection": 242,
                    "text": "New evidence suggests that microbes are also present in many tumors, though the scope of how they affect tumor biology and clinical outcomes is in its early stages.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37901238",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 73,
                    "text": "The tumor microbiome (TM) has been linked to pancreatic cancer prognosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Relevance of tumoral microbiome.",
            "type": "summary",
            "id": "660c0895fdcbea915f00002f",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23835333",
                "http://www.ncbi.nlm.nih.gov/pubmed/37158990",
                "http://www.ncbi.nlm.nih.gov/pubmed/37861217",
                "http://www.ncbi.nlm.nih.gov/pubmed/37004543",
                "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
                "http://www.ncbi.nlm.nih.gov/pubmed/37878676",
                "http://www.ncbi.nlm.nih.gov/pubmed/22968521",
                "http://www.ncbi.nlm.nih.gov/pubmed/26364507",
                "http://www.ncbi.nlm.nih.gov/pubmed/35533645",
                "http://www.ncbi.nlm.nih.gov/pubmed/37937833"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23835333",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 358,
                    "text": "Our aim was to determine whether two courses of teplizumab, an Fc receptor-nonbinding anti-CD3 monoclonal antibody, reduces the decline in C-peptide levels in patients with T1D 2 years after disease onset.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37158990",
                    "offsetInBeginSection": 1004,
                    "offsetInEndSection": 1198,
                    "text": "Teplizumab, a monoclonal antibody (manufactured by Provention Bio and marketed as Tzield), was recently approved by the Food and Drug Administration as the first preventative treatment for T1DM.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37861217",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 239,
                    "text": "Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or older with preclinical (stage 2) disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37004543",
                    "offsetInBeginSection": 426,
                    "offsetInEndSection": 511,
                    "text": "Teplizumab is a novel drug recently approved by the US FDA for the treatment of T1DM.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
                    "offsetInBeginSection": 503,
                    "offsetInEndSection": 744,
                    "text": "One of the most promising agents, teplizumab , is an FcR-nonbinding anti-CD3 monoclonal antibody that has been tested in Phase II - III clinical trials and was shown to preserve the C-peptide levels and reduce the need for exogenous insulin.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23835333",
                    "offsetInBeginSection": 1146,
                    "offsetInEndSection": 1290,
                    "text": "We conclude that teplizumab treatment preserves insulin production and reduces the use of exogenous insulin in some patients with new-onset T1D.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37878676",
                    "offsetInBeginSection": 84,
                    "offsetInEndSection": 271,
                    "text": "For example, treatment with the T cell-specific anti-CD3 antibody teplizumab delayed disease onset in participants at high risk for type 1 diabetes (T1D) in the TrialNet 10 (TN-10) trial.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22968521",
                    "offsetInBeginSection": 1121,
                    "offsetInEndSection": 1406,
                    "text": "both Phase 2 and Phase 3 studies have demonstrated preserved C-peptide response as a measure of insulin production, decreased exogenous insulin use, and improved glycemic control following a 12- to 14-day teplizumab infusion in patients diagnosed with T1DM within the previous 6 weeks.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26364507",
                    "offsetInBeginSection": 1010,
                    "offsetInEndSection": 1162,
                    "text": "The immunosuppressants (teplizumab, rituximab and abatacept) show promise in slowing the T1DM progressions for a specific subpopulation of T1DM patients",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35533645",
                    "offsetInBeginSection": 1134,
                    "offsetInEndSection": 1287,
                    "text": "teplizumab was the first immunomodulatory agent to demonstrate a significant delay in disease progression in high-risk individuals before clinical onset.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What disease is treated with Teplizumab?",
            "type": "factoid",
            "id": "65cf6ae91930410b13000007",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31619389",
                "http://www.ncbi.nlm.nih.gov/pubmed/28783173",
                "http://www.ncbi.nlm.nih.gov/pubmed/35563059"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31619389",
                    "offsetInBeginSection": 332,
                    "offsetInEndSection": 368,
                    "text": "the target, the MDM2-p53 interaction",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783173",
                    "offsetInBeginSection": 402,
                    "offsetInEndSection": 617,
                    "text": "The combination of pimasertib (MEK inhibitor) and SAR405838 (MDM2 inhibitor) was synergistic and induced the expression of PUMA and BIM, led to apoptosis and growth inhibition in vitro, and tumor regression in vivo.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31619389",
                    "offsetInBeginSection": 152,
                    "offsetInEndSection": 252,
                    "text": "SAR405838 is a novel molecularly targeted agent that is in clinical trials for various solid tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35563059",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Indoleamine 2,3-dioxygenase 1 (IDO1) is an attractive heme enzyme for its significant function in cancer immunotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35563059",
                    "offsetInBeginSection": 462,
                    "offsetInEndSection": 544,
                    "text": "the inhibitory activity of spiro-oxindole skeleton compounds to IDO1 was evaluated",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the target of Divarasib?",
            "type": "factoid",
            "id": "65cfaf7e1930410b13000016",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19185015",
                "http://www.ncbi.nlm.nih.gov/pubmed/15912504",
                "http://www.ncbi.nlm.nih.gov/pubmed/25501368",
                "http://www.ncbi.nlm.nih.gov/pubmed/11590238",
                "http://www.ncbi.nlm.nih.gov/pubmed/20589833",
                "http://www.ncbi.nlm.nih.gov/pubmed/26359495",
                "http://www.ncbi.nlm.nih.gov/pubmed/19617396",
                "http://www.ncbi.nlm.nih.gov/pubmed/15998321",
                "http://www.ncbi.nlm.nih.gov/pubmed/28314111",
                "http://www.ncbi.nlm.nih.gov/pubmed/19103232"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19185015",
                    "offsetInBeginSection": 209,
                    "offsetInEndSection": 397,
                    "text": "Membrane fusion is mediated by soluble N-ethylmaleimide-sensitive factor attachment protein receptor proteins (SNAREs), which act by specific pairing of vesicle (R)- and target (Q)-SNAREs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15912504",
                    "offsetInBeginSection": 899,
                    "offsetInEndSection": 1280,
                    "text": "Syntaxin-1, a core protein of the soluble N-ethylmaleimide-sensitive-factor attachment protein receptor (SNARE) complex known to bind to complexin, and synapsin I, a synaptic vesicle-associated protein involved in the Ca(2+)-dependent recruitment of synaptic vesicles for transmitter release, were also present in the horizontal cells and their processes at photoreceptor synapses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25501368",
                    "offsetInBeginSection": 113,
                    "offsetInEndSection": 333,
                    "text": "This process is mediated by the formation of functional soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complexes between the plasma membrane t-SNARE complex and the vesicle v-SNARE or VAMP.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11590238",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "Syntaxins are target-soluble N-ethylmaleimide-sensitive factor-attachment protein receptors (t-SNAREs) involved in docking and fusion of vesicles in exocytosis and endocytosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20589833",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "text": "Syntaxin 16 (Syx16) is member of the soluble N-ethylmaleimide sensitive factor attachment protein receptor (SNARE) family of molecules that functions in membrane fusion in eukaryotic cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26359495",
                    "offsetInBeginSection": 262,
                    "offsetInEndSection": 404,
                    "text": "SNAP-47 mainly localized to cytoplasm, the endoplasmic reticulum (ER), and ERGIC and could also shuttle between the cytoplasm and the nucleus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19617396",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "text": "The specificity of vesicle-mediated transport is largely regulated by the membrane-specific distribution of SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19185015",
                    "offsetInBeginSection": 1342,
                    "offsetInEndSection": 1643,
                    "text": "This study provides a comprehensive analysis of SNARE proteins in oligodendrocytes and assigns defined SNAREs to putative vesicle trafficking pathways in myelinating oligodendrocytes, thus facilitating future functional analysis of distinct SNAREs in oligodendroglial membrane traffic and myelination.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15998321",
                    "offsetInBeginSection": 129,
                    "offsetInEndSection": 355,
                    "text": "These soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins are believed to be involved in tubulovesicle trafficking and membrane fusion during the secretory cycle of the gastric parietal cell.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28314111",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "text": "Soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins are essential constituents of the intracellular trafficking machinery.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "In what part of the cell would a SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) be found",
            "type": "factoid",
            "id": "66088d66fdcbea915f00000c",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27450525",
                "http://www.ncbi.nlm.nih.gov/pubmed/30747118",
                "http://www.ncbi.nlm.nih.gov/pubmed/1730177",
                "http://www.ncbi.nlm.nih.gov/pubmed/20801003",
                "http://www.ncbi.nlm.nih.gov/pubmed/37885152",
                "http://www.ncbi.nlm.nih.gov/pubmed/27041139",
                "http://www.ncbi.nlm.nih.gov/pubmed/21488832",
                "http://www.ncbi.nlm.nih.gov/pubmed/23163834",
                "http://www.ncbi.nlm.nih.gov/pubmed/24828901",
                "http://www.ncbi.nlm.nih.gov/pubmed/8256507"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27450525",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 69,
                    "text": "Rabies is a zoonosis ending fatally in all mammals, including humans.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30747118",
                    "offsetInBeginSection": 185,
                    "offsetInEndSection": 363,
                    "text": "No other known infectious disease can cause 100% mortality, and rabies and the clinical manifestations which precede a death from the disease are often described as excruciating.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30747118",
                    "offsetInBeginSection": 525,
                    "offsetInEndSection": 626,
                    "text": "However, rabies is also one of the few infectious diseases that can be prevented through vaccination.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1730177",
                    "offsetInBeginSection": 1263,
                    "offsetInEndSection": 1306,
                    "text": "If left untreated, rabies is usually fatal.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20801003",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Unlike any other human infection, encephalitis caused by dog rabies virus is always fatal.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37885152",
                    "offsetInBeginSection": 259,
                    "offsetInEndSection": 423,
                    "text": "Rabies is entirely preventable through proper vaccination, and thus, the highest incidence is typically observed in developing countries, mainly in Africa and Asia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27041139",
                    "offsetInBeginSection": 172,
                    "offsetInEndSection": 271,
                    "text": "Although preventable by vaccination, rabies causes c. 59,000 human fatalities every year worldwide.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21488832",
                    "offsetInBeginSection": 229,
                    "offsetInEndSection": 466,
                    "text": "Since the first implementation, by Louis Pasteur in 1885, of an efficient preventive post-exposure treatment, more effective protocols and safer products have been developed, providing almost 100% protection if administered early enough.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23163834",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "Rabies is a rapidly progressive lyssavirus encephalitis that is statistically 100% fatal.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24828901",
                    "offsetInBeginSection": 362,
                    "offsetInEndSection": 432,
                    "text": "Almost all cases of human rabies result from bites from infected dogs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Without immunization, rabies is a lethal disease.",
            "type": "yesno",
            "id": "660d6a97fdcbea915f00003c",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30060184",
                "http://www.ncbi.nlm.nih.gov/pubmed/33057331",
                "http://www.ncbi.nlm.nih.gov/pubmed/18460012",
                "http://www.ncbi.nlm.nih.gov/pubmed/28245596",
                "http://www.ncbi.nlm.nih.gov/pubmed/26261303",
                "http://www.ncbi.nlm.nih.gov/pubmed/37246715",
                "http://www.ncbi.nlm.nih.gov/pubmed/18373493",
                "http://www.ncbi.nlm.nih.gov/pubmed/16648478",
                "http://www.ncbi.nlm.nih.gov/pubmed/15485916",
                "http://www.ncbi.nlm.nih.gov/pubmed/30204891"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30060184",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 240,
                    "text": "Diphthamide is a modified histidine residue which is uniquely present in archaeal and eukaryotic elongation factor 2 (EF-2), an essential GTPase responsible for catalyzing the coordinated translocation of tRNA and mRNA through the ribosome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33057331",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "text": "Diphthamide is a unique post-translationally modified histidine residue (His715 in all mammals) found only in eukaryotic elongation factor-2 (eEF-2).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18460012",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "Diphthamide is a post-translational derivative of histidine in protein synthesis elongation factor-2 (eEF-2) that is present in all eukaryotes with no known normal physiological role.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28245596",
                    "offsetInBeginSection": 1605,
                    "offsetInEndSection": 1742,
                    "text": "Sensitivity to ADP-ribosylating toxins and tumor-targeted immunotoxins depends on diphthamide which, in turn, requires DPH functionality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28245596",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "text": "The diphthamide on eukaryotic translation elongation factor 2 (eEF2) is the target of ADPribosylating toxins and -derivatives that serve as payloads in targeted tumor therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26261303",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "Loss of diphthamide pre-activates NF-B and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor.",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18460012",
                    "offsetInBeginSection": 407,
                    "offsetInEndSection": 567,
                    "text": "We found that diphthamide-deficient cultured cells were threefold more sensitive than their parental cells towards ricin, a ribosome-inactivating protein (RIP).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18460012",
                    "offsetInBeginSection": 1186,
                    "offsetInEndSection": 1374,
                    "text": "These data show that the presence of diphthamide in eEF-2 provides protection against ricin and suggest the hypothesis that diphthamide may have evolved to provide protection against RIPs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26261303",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "The diphthamide on human eukaryotic translation elongation factor 2 (eEF2) is the target of ADP ribosylating diphtheria toxin (DT) and Pseudomonas exotoxin A (PE).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33057331",
                    "offsetInBeginSection": 292,
                    "offsetInEndSection": 523,
                    "text": "Diphthamide is not only essential for normal physiology (such as ensuring fidelity of mRNA translation), but is also exploited by bacterial ADP-ribosylating toxins (e.g., diphtheria toxin) as their molecular target in pathogenesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the function of Diphthamide?",
            "type": "summary",
            "id": "66088bbafdcbea915f00000a",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33194604",
                "http://www.ncbi.nlm.nih.gov/pubmed/30857956",
                "http://www.ncbi.nlm.nih.gov/pubmed/33961795",
                "http://www.ncbi.nlm.nih.gov/pubmed/27108243",
                "http://www.ncbi.nlm.nih.gov/pubmed/35238866",
                "http://www.ncbi.nlm.nih.gov/pubmed/29990497",
                "http://www.ncbi.nlm.nih.gov/pubmed/23281932",
                "http://www.ncbi.nlm.nih.gov/pubmed/34572729",
                "http://www.ncbi.nlm.nih.gov/pubmed/27341591",
                "http://www.ncbi.nlm.nih.gov/pubmed/34999585"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33194604",
                    "offsetInBeginSection": 615,
                    "offsetInEndSection": 790,
                    "text": "For patients with HER2-positive mCRC, who have developed resistance to trastuzumab and lapatinib, pyrotinib is a promising new candidate, which can be used as salvage therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30857956",
                    "offsetInBeginSection": 2230,
                    "offsetInEndSection": 2436,
                    "text": "Dual HER2-targeted therapy with pertuzumab plus trastuzumab is well tolerated and could represent a therapeutic opportunity for patients with heavily pretreated, HER2-amplified metastatic colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33961795",
                    "offsetInBeginSection": 1615,
                    "offsetInEndSection": 1850,
                    "text": "Trastuzumab deruxtecan showed promising and durable activity in HER2-positive metastatic colorectal cancer refractory to standard treatment, with a safety profile consistent with that reported in previous trastuzumab deruxtecan trials.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27108243",
                    "offsetInBeginSection": 2362,
                    "offsetInEndSection": 2517,
                    "text": "The combination of trastuzumab and lapatinib is active and well tolerated in treatment-refractory patients with HER2-positive metastatic colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35238866",
                    "offsetInBeginSection": 553,
                    "offsetInEndSection": 745,
                    "text": "Recent evidence indicates that anti-ERBB2 therapeutic strategies are active in patients with ERBB2-positive metastatic colorectal cancer and could potentially represent a new standard-of-care.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29990497",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Targeting HER2 is effective in 24% of ERBB2 amplified metastatic colorectal cancer; however, secondary resistance occurs in most of the cases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23281932",
                    "offsetInBeginSection": 717,
                    "offsetInEndSection": 1028,
                    "text": "An increasing number of molecular alterations have been more recently hypothesized to be involved in resistance to anti-EGFR mAbs in CRC: mutations in BRAF, NRAS and PIK3CA, loss of expression of PTEN and, now, activation of HER2 signaling through HER2 gene amplification and/or increased heregulin stimulation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34572729",
                    "offsetInBeginSection": 836,
                    "offsetInEndSection": 1135,
                    "text": "Here, we will review the molecular underpinnings and clinical data supporting novel targeted treatments under development for refractory mCRC harboring BRAF mutations, KRAS G12C mutations, HER2 amplification, and less common molecular alterations, such as the re-arrangements of NTRK, ALK, and ROS1.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27341591",
                    "offsetInBeginSection": 728,
                    "offsetInEndSection": 850,
                    "text": "Some of them have been validated as targets for therapeutic intervention in clinical trials, such as ERBB2 amplifications.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34999585",
                    "offsetInBeginSection": 951,
                    "offsetInEndSection": 1211,
                    "text": "Rechallenge with anti-EGFR inhibitors, in case of persistent or recovery of RAS-wildness, and targeted approach of specific mutations (BRAF inhibitors), amplifications (anti-Her2 treatment), or fusion proteins (NTRK inhibitors) can by guided by the use of NGS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients?",
            "type": "factoid",
            "id": "65f77a71c4010b4d7800003b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33402412",
                "http://www.ncbi.nlm.nih.gov/pubmed/26463698",
                "http://www.ncbi.nlm.nih.gov/pubmed/24588789",
                "http://www.ncbi.nlm.nih.gov/pubmed/26645254",
                "http://www.ncbi.nlm.nih.gov/pubmed/35012462",
                "http://www.ncbi.nlm.nih.gov/pubmed/21609410",
                "http://www.ncbi.nlm.nih.gov/pubmed/25465108",
                "http://www.ncbi.nlm.nih.gov/pubmed/16682611",
                "http://www.ncbi.nlm.nih.gov/pubmed/11306778",
                "http://www.ncbi.nlm.nih.gov/pubmed/31105976"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33402412",
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 291,
                    "text": "The 2016 meta-analysis and 2017 Cochrane review showed that transdermal GTN was beneficial in a small patient subgroup with stroke onset 6 hours.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26463698",
                    "offsetInBeginSection": 1501,
                    "offsetInEndSection": 1702,
                    "text": "In a subgroup analysis of the large ENOS trial, transdermal GTN was safe to administer and associated with improved functional outcome and fewer deaths when administered within 6 hours of stroke onset.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24588789",
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 372,
                    "text": "The 'Efficacy of Nitric Oxide in Stroke' trial tested whether transdermal glyceryl trinitrate, a nitric oxide donor that lowers blood pressure, is safe and effective in improving outcome after acute stroke.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26645254",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 215,
                    "text": "The Efficacy of Nitric Oxide in Stroke (ENOS) trial found that transdermal glyceryl trinitrate (GTN, a nitric oxide donor) lowered blood pressure but did not improve functional outcome in patients with acute stroke.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33402412",
                    "offsetInBeginSection": 368,
                    "offsetInEndSection": 504,
                    "text": "We report the protocol for an updated systematic review and meta-analysis on the safety and benefits of transdermal GTN in acute stroke.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35012462",
                    "offsetInBeginSection": 1465,
                    "offsetInEndSection": 1667,
                    "text": "At 90 days, the GTN group had a better mRS score as compared to the sham group (adjusted common odds ratio 0.54; 95% confidence intervals 0.34, 0.85; p = 0.008), a difference that persisted at 365 days.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35012462",
                    "offsetInBeginSection": 1964,
                    "offsetInEndSection": 2150,
                    "text": "GTN was associated with unexplained improved functional outcome observed at 90 days and one year, a finding that may represent an undetected baseline imbalance, chance, or real efficacy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35012462",
                    "offsetInBeginSection": 2151,
                    "offsetInEndSection": 2184,
                    "text": "GTN was not associated with harm.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21609410",
                    "offsetInBeginSection": 1766,
                    "offsetInEndSection": 1957,
                    "text": "Transdermal glyceryl trinitrate (5 mg) significantly lowered 24 h blood pressure by 9/5 mmHg (equivalent to a 6% reduction) in both dipping and nondipping patients with acute/subacute stroke.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25465108",
                    "offsetInBeginSection": 1869,
                    "offsetInEndSection": 2044,
                    "text": "In patients with acute stroke and high blood pressure, transdermal glyceryl trinitrate lowered blood pressure and had acceptable safety but did not improve functional outcome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is transdermal glyceryl trinitrate effective for stroke?",
            "type": "yesno",
            "id": "65d136081930410b1300003a",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21063317",
                "http://www.ncbi.nlm.nih.gov/pubmed/32548189",
                "http://www.ncbi.nlm.nih.gov/pubmed/28270902",
                "http://www.ncbi.nlm.nih.gov/pubmed/8456263",
                "http://www.ncbi.nlm.nih.gov/pubmed/28688949",
                "http://www.ncbi.nlm.nih.gov/pubmed/15631226",
                "http://www.ncbi.nlm.nih.gov/pubmed/29749329",
                "http://www.ncbi.nlm.nih.gov/pubmed/15859547",
                "http://www.ncbi.nlm.nih.gov/pubmed/26336025",
                "http://www.ncbi.nlm.nih.gov/pubmed/29255772"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21063317",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 347,
                    "text": "Few children display CNS symptoms such as peripheral neuropathy and cerebellar ataxia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32548189",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "text": "Dysphagia is an uncommon symptom for celiac disease (CD). Typically, patients with CD present with abdominal pain, diarrhea, steatorrhea, weight loss, growth failure, anemia, or fatigue.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28270902",
                    "offsetInBeginSection": 201,
                    "offsetInEndSection": 278,
                    "text": "Abortive illness is a rare symptom leading to the detection of cliac disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8456263",
                    "offsetInBeginSection": 575,
                    "offsetInEndSection": 702,
                    "text": "Laryngospasm is a rare symptom of hypocalcemia and has not, to our knowledge, been described in the context of coeliac disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688949",
                    "offsetInBeginSection": 1097,
                    "offsetInEndSection": 1304,
                    "text": "The presence of enamel defects and/or aphthous stomatitis in a child affected by other typical or atypical symptoms of celiac disease represents an indication for further diagnostic exams for celiac disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15631226",
                    "offsetInBeginSection": 78,
                    "offsetInEndSection": 150,
                    "text": "Most sufferers show atypical symptoms and might well remain undiagnosed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29749329",
                    "offsetInBeginSection": 262,
                    "offsetInEndSection": 398,
                    "text": "In addition to the classical symptoms of the disease such as diarrhea and weight loss, the incidence of atypical symptoms is increasing.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15859547",
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 291,
                    "text": "Various atypical symptoms and extraintestinal manifestations were observed in older children (above 7 years) and in adults.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26336025",
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 440,
                    "text": "presented with diarrhea, headache, insomnia, loss of appetite, abnormal taste, and impaired short-term memory and concentration, but with no skin lesions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255772",
                    "offsetInBeginSection": 239,
                    "offsetInEndSection": 423,
                    "text": "We report the case of a 53-year-old man presenting with neuromuscular symptoms, skin rash, inconspicuous chronic diarrhea, marked weight loss, and biochemical markers of malabsorption.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are atypical symptoms of gluten allergy?",
            "type": "list",
            "id": "660d2d6afdcbea915f00003b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37675463",
                "http://www.ncbi.nlm.nih.gov/pubmed/30312900",
                "http://www.ncbi.nlm.nih.gov/pubmed/24140707",
                "http://www.ncbi.nlm.nih.gov/pubmed/26261303",
                "http://www.ncbi.nlm.nih.gov/pubmed/34507998",
                "http://www.ncbi.nlm.nih.gov/pubmed/8175783",
                "http://www.ncbi.nlm.nih.gov/pubmed/22869748"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37675463",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "text": "The autosomal-recessive diphthamide deficiency syndrome presents as intellectual disability with developmental abnormalities, seizures, craniofacial and additional morphological phenotypes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30312900",
                    "offsetInBeginSection": 365,
                    "offsetInEndSection": 564,
                    "text": "Additional phenotypes resulting from diphthamide deficiency include altered tRNA-synthetase and selenoprotein transcript levels, hypersensitivity to oxidative stress and increased selenite tolerance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140707",
                    "offsetInBeginSection": 1135,
                    "offsetInEndSection": 1336,
                    "text": "Our findings therefore suggest that eEF2 diphthamide controls the selective translation of IRES-dependent protein targets XIAP and FGF2, critical for cell survival under conditions of oxidative stress.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26261303",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "Loss of diphthamide pre-activates NF-B and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor.",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140707",
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 637,
                    "text": "Under high oxidative stress conditions diphthamide-deficient cells were significantly more sensitive to cell death.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34507998",
                    "offsetInBeginSection": 490,
                    "offsetInEndSection": 592,
                    "text": "Diphthamide deficiency in yeast suppresses the translation of TORC1-activating proteins Vam6 and Rtc1.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37675463",
                    "offsetInBeginSection": 190,
                    "offsetInEndSection": 304,
                    "text": "It is caused by reduced activity of proteins that synthesize diphthamide on human translation elongation factor 2.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8175783",
                    "offsetInBeginSection": 1058,
                    "offsetInEndSection": 1175,
                    "text": "However, the viable cells grew more slowly than cells expressing wild-type EF-2 and showed temperature sensitivities.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22869748",
                    "offsetInBeginSection": 513,
                    "offsetInEndSection": 612,
                    "text": "eEF2(G717R/G717R) MEFs retain full activity in polypeptide elongation and have normal growth rates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8175783",
                    "offsetInBeginSection": 929,
                    "offsetInEndSection": 1057,
                    "text": "In the Group 3 mutants, EF-2 was not ribosylated by diphtheria toxin, indicating that the mutant EF-2s did not form diphthamide.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the results of diphthamide deficiency?",
            "type": "summary",
            "id": "660a912dfdcbea915f000028",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35100726",
                "http://www.ncbi.nlm.nih.gov/pubmed/26970120",
                "http://www.ncbi.nlm.nih.gov/pubmed/38033501",
                "http://www.ncbi.nlm.nih.gov/pubmed/32779393",
                "http://www.ncbi.nlm.nih.gov/pubmed/30696689",
                "http://www.ncbi.nlm.nih.gov/pubmed/37934000",
                "http://www.ncbi.nlm.nih.gov/pubmed/25993165",
                "http://www.ncbi.nlm.nih.gov/pubmed/36636028",
                "http://www.ncbi.nlm.nih.gov/pubmed/37217528",
                "http://www.ncbi.nlm.nih.gov/pubmed/25176973"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35100726",
                    "offsetInBeginSection": 575,
                    "offsetInEndSection": 747,
                    "text": "Basket trials have been devised to ascertain the extent to which a treatment strategy offers benefit to various patient subpopulations defined by a common molecular target.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26970120",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 242,
                    "text": "Basket clinical trials are a new category of early clinical trials in which a treatment is evaluated in a population of patients with tumors of various histologic types and primary sites selected for containing specific genomic abnormalities.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38033501",
                    "offsetInBeginSection": 233,
                    "offsetInEndSection": 404,
                    "text": "Participants are grouped into so-called baskets according to tumor type, allowing investigators to identify tumors with promising responses to treatment for further study.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32779393",
                    "offsetInBeginSection": 89,
                    "offsetInEndSection": 241,
                    "text": "A basket trial is a type of clinical trial for which eligibility is based on the presence of a specific genomic alteration, irrespective of cancer type.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30696689",
                    "offsetInBeginSection": 782,
                    "offsetInEndSection": 989,
                    "text": "In contrast, basket studies generally enroll patients with different tumor types based on the presence of a specific mutation or biomarker regardless of histology; these trials may include expansion cohorts.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37934000",
                    "offsetInBeginSection": 753,
                    "offsetInEndSection": 942,
                    "text": "The design of basket trials involves screening patients for specific molecular alterations or biomarkers and enrolling them in the trial to receive the targeted therapy under investigation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25993165",
                    "offsetInBeginSection": 562,
                    "offsetInEndSection": 781,
                    "text": "Basket trial designs offer the possibility to include multiple molecularly defined subpopulations, often across histology or tumor types, but included in one cohesive design to evaluate the targeted therapy in question.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36636028",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170,
                    "text": "Basket trials are an innovative precision medicine clinical trial design evaluating a single targeted therapy across multiple diseases that share a common characteristic.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37217528",
                    "offsetInBeginSection": 824,
                    "offsetInEndSection": 1053,
                    "text": "We present novel geometric methods (mathematical theory of hypersurfaces) to visualise complex cancer therapeutics data as multidimensional, as well as geometric representation of oncology trial design space in higher dimensions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25176973",
                    "offsetInBeginSection": 534,
                    "offsetInEndSection": 703,
                    "text": "Basket trials are often viewed as parallel phase II trials within the same entity, designed on the basis of a common denominator, which can be a molecular alteration(s).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is a basket trial?",
            "type": "summary",
            "id": "66088f67fdcbea915f00000e",
            "ideal_answer": ""
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What are active ingredients of Xultophy pill?",
            "type": "list",
            "id": "65d375011930410b1300004a",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "Should UGT1A1 alteration be routinely determined in colorectal cancer patients?",
            "type": "yesno",
            "id": "65f775e8c4010b4d7800002d",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29979678",
                "http://www.ncbi.nlm.nih.gov/pubmed/29148907",
                "http://www.ncbi.nlm.nih.gov/pubmed/30063520",
                "http://www.ncbi.nlm.nih.gov/pubmed/26384556"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29979678",
                    "offsetInBeginSection": 545,
                    "offsetInEndSection": 671,
                    "text": "Trained healthcare providers held an ACP meeting to discuss patients' preference regarding end-of-life care and AD completion.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29979678",
                    "offsetInBeginSection": 948,
                    "offsetInEndSection": 1056,
                    "text": "Of the 1411 patients who received ACP communication with complete data, the rate of AD completion was 82.6%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29148907",
                    "offsetInBeginSection": 1405,
                    "offsetInEndSection": 1586,
                    "text": "Many patients preferred to entrust the end-of-life decisions to others rather than utilizing advance directives, which made surrogates more dependent on doctors for decision making.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30063520",
                    "offsetInBeginSection": 1048,
                    "offsetInEndSection": 1236,
                    "text": "Top 3 common obstacle experiences included families in denial, families going against patient wishes and advanced directives, and families directing care that negatively impacted patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26384556",
                    "offsetInBeginSection": 1206,
                    "offsetInEndSection": 1421,
                    "text": "Presence of a living will and dying in the setting of full support mediated the relationship between patient race and family ratings; patient race exerted an indirect, rather than direct, effect on quality of dying.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Are advanced directives an expression of the patient's wishes for future care in case they become cognitively impaired or find themselves in critical condition?",
            "type": "yesno",
            "id": "65f84eadc4010b4d7800004c",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37870968"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37870968",
                    "offsetInBeginSection": 1280,
                    "offsetInEndSection": 1538,
                    "text": "In this phase 3 trial of a KRAS G12C inhibitor plus an EGFR inhibitor in patients with chemorefractory metastatic colorectal cancer, both doses of sotorasib in combination with panitumumab resulted in longer progression-free survival than standard treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which drugs were tested in the CodeBreaK 300 clinical trial?",
            "type": "list",
            "id": "65cf69541930410b13000006",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35488243",
                "http://www.ncbi.nlm.nih.gov/pubmed/37364479",
                "http://www.ncbi.nlm.nih.gov/pubmed/36969071",
                "http://www.ncbi.nlm.nih.gov/pubmed/37841750",
                "http://www.ncbi.nlm.nih.gov/pubmed/36831641",
                "http://www.ncbi.nlm.nih.gov/pubmed/37696895",
                "http://www.ncbi.nlm.nih.gov/pubmed/37205307",
                "http://www.ncbi.nlm.nih.gov/pubmed/32580024",
                "http://www.ncbi.nlm.nih.gov/pubmed/31293523",
                "http://www.ncbi.nlm.nih.gov/pubmed/30995949"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35488243",
                    "offsetInBeginSection": 528,
                    "offsetInEndSection": 811,
                    "text": "Notably, one of the primary modes by which the gut microbiota modulate antitumor immunity is by means of metabolites, which are small molecules that could spread from their initial location of the gut and impact local and systemic antitumor immune response to promote ICI efficiency.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35488243",
                    "offsetInBeginSection": 350,
                    "offsetInEndSection": 527,
                    "text": "Deciphering the underlying mechanisms reveals that the gut microbiota reprogram the immunity of the tumor microenvironment (TME) by engaging innate and/or adaptive immune cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37364479",
                    "offsetInBeginSection": 254,
                    "offsetInEndSection": 440,
                    "text": "The gut microbiota can affect both anti-tumor and pro-tumor immune responses, and further modulate the efficacy of cancer immunotherapy, particularly in the context of therapy with ICIs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36969071",
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 534,
                    "text": "Gut microbiota has been shown critical for the development of different cancer types, and the potential of gut microbiota manipulation through direct implantation or antibiotic-based depletion in regulating the overall efficacy of cancer immunotherapies has also been evaluated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37364479",
                    "offsetInBeginSection": 441,
                    "offsetInEndSection": 647,
                    "text": "Therefore, a deeper understanding of how the gut microbiota modulates immune responses is crucial to improve the outcomes of CRC patients receiving immunotherapy and to overcome resistance in nonresponders.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37841750",
                    "offsetInBeginSection": 786,
                    "offsetInEndSection": 1082,
                    "text": "By shifting the gut microbiota to the 'favorable' one through various modifications, preclinical and clinical studies have yielded more pronounced responses and better clinical outcomes when combined with ICIs treatment, providing novel approaches to improve the efficacy of cancer immunotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36831641",
                    "offsetInBeginSection": 997,
                    "offsetInEndSection": 1189,
                    "text": "Here we elucidate the immune-interactive mechanisms underlying the effects of these microbially derived vitamins and how they can potentially enhance the activity of immunotherapies in cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37696895",
                    "offsetInBeginSection": 480,
                    "offsetInEndSection": 634,
                    "text": "Interestingly, the efficacy of cancer immunotherapies that manipulate costimulatory and coinhibitory pathways has been correlated with the gut microbiota.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37696895",
                    "offsetInBeginSection": 903,
                    "offsetInEndSection": 1028,
                    "text": "Here, we review mechanisms by which commensal microorganisms signal immune cells and their potential impact on costimulation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37205307",
                    "offsetInBeginSection": 719,
                    "offsetInEndSection": 929,
                    "text": "Actually, mounting research has shown that the gut microbiota plays a crucial role in regulating the host immune response and boosting the efficacy of anticancer medications like chemotherapy and immunotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the mechanism by which the microbiota modulates the effectiveness of immunotherapy?",
            "type": "summary",
            "id": "65f7794dc4010b4d78000037",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35352512",
                "http://www.ncbi.nlm.nih.gov/pubmed/36949951",
                "http://www.ncbi.nlm.nih.gov/pubmed/35958603",
                "http://www.ncbi.nlm.nih.gov/pubmed/35619103"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35352512",
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 630,
                    "text": "Considering the amazing therapeutic effect of immune check point inhibitors for metastatic colorectal cancer, we conduct this multicenter, phase Ib study to investigate the safety and efficacy of anti-PD-1 antibody, sintilimab combined with hypofractionated radiotherapy in MSI-H/dMMR rectal cancer patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36949951",
                    "offsetInBeginSection": 669,
                    "offsetInEndSection": 877,
                    "text": "Due to the special features of biologics in MSI-H/dMMR CRC patients, this subgroup of patients achieved little treatment efficacy from chemoradiotherapy but benefited from immune checkpoint inhibitors (ICIs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36949951",
                    "offsetInBeginSection": 1026,
                    "offsetInEndSection": 1202,
                    "text": "Given the better systemic immune function, increased antigenic exposure, and improved long-term memory induction before surgery, neoadjuvant ICI (NAICI) treatment was proposed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35958603",
                    "offsetInBeginSection": 2173,
                    "offsetInEndSection": 2453,
                    "text": "Neoadjuvant monoimmunotherapy with PD-1 inhibitor has favorable ORR and pCR rate, and relatively low incidences of irAEs and srAEs for patients with dMMR/MSI-H LACRC, suggesting that this nIT regimen of single-agent PD-1 inhibitor is significantly effective and sufficiently safe.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35619103",
                    "offsetInBeginSection": 2165,
                    "offsetInEndSection": 2284,
                    "text": "This result suggests that nivolumab in addition to TNT can be an option as a preoperative strategy for LARC with MSI-H.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35619103",
                    "offsetInBeginSection": 2053,
                    "offsetInEndSection": 2164,
                    "text": "A case of LARC with MSI-H was treated with TNT with nivolumab, resulting in pCR and complete radical resection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36949951",
                    "offsetInBeginSection": 1203,
                    "offsetInEndSection": 1366,
                    "text": "The NICHE trial pioneered the use of NAICI treatment in LACRC, and recent reports from several phase II studies demonstrated satisfactory tumour downsizing in CRC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35352512",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "Neoadjuvant radiochemotherapy followed by radical surgery is the standard treatment strategy for local advanced rectal cancer (LARC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36949951",
                    "offsetInBeginSection": 531,
                    "offsetInEndSection": 668,
                    "text": "According to mismatch repair protein expression, MSI-H/dMMR and non-MSI-H/pMMR statuses were defined in colorectal cancer (CRC) patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is surgical resection an appropriate treatment over immunotherapy in MSI-H locally advanced rectal cancer patients?",
            "type": "yesno",
            "id": "65f779edc4010b4d78000039",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What type of drug is administered to the mother for the prevention of lung immaturity when a preterm delivery is anticipated?",
            "type": "factoid",
            "id": "660bb7f9fdcbea915f000029",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12785743",
                "http://www.ncbi.nlm.nih.gov/pubmed/12794666",
                "http://www.ncbi.nlm.nih.gov/pubmed/9746449",
                "http://www.ncbi.nlm.nih.gov/pubmed/18638174",
                "http://www.ncbi.nlm.nih.gov/pubmed/15247538",
                "http://www.ncbi.nlm.nih.gov/pubmed/15377732",
                "http://www.ncbi.nlm.nih.gov/pubmed/18558468",
                "http://www.ncbi.nlm.nih.gov/pubmed/15224712",
                "http://www.ncbi.nlm.nih.gov/pubmed/21179620",
                "http://www.ncbi.nlm.nih.gov/pubmed/9254767"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12785743",
                    "offsetInBeginSection": 310,
                    "offsetInEndSection": 482,
                    "text": "Sydenham's chorea is triggered by streptococcal pharyngitis, the most important component of its therapy is antibiotic prophylaxis against further streptococcal infections.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12785743",
                    "offsetInBeginSection": 483,
                    "offsetInEndSection": 732,
                    "text": "Because the pathogenesis of Sydenham's chorea includes the production of anti-basal ganglia antibodies, therapies that modulate immune function or that restore neurotransmitter balance within the basal ganglia may be effective for Sydenham's chorea.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12794666",
                    "offsetInBeginSection": 711,
                    "offsetInEndSection": 834,
                    "text": "The role of the autoimmune mechanisms and the dysfunction of the basal ganglia have been demonstrated in Sydenham's chorea.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12794666",
                    "offsetInBeginSection": 447,
                    "offsetInEndSection": 631,
                    "text": "Sydenham's chorea is a neuropsychiatric disorder that may present with emotional lability, anxiety, obsessive compulsive symptoms, attention deficit and hyperactivity symptoms or tics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9746449",
                    "offsetInBeginSection": 596,
                    "offsetInEndSection": 695,
                    "text": "Sydenham's chorea is a symptom of rheumatic fever and results from an autoimmune attack on the CNS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18638174",
                    "offsetInBeginSection": 321,
                    "offsetInEndSection": 424,
                    "text": "It is vital that each case of streptococcal pharyngitis be treated with appropriate antibiotic therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18638174",
                    "offsetInBeginSection": 425,
                    "offsetInEndSection": 565,
                    "text": "Doing so will help prevent the sequelae associated with streptococcal infections, such as acute rheumatic fever (ARF) and Sydenham's chorea.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15247538",
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 365,
                    "text": "Interest has also been growing in the possibility that the mechanism responsible for Sydenham's chorea plays a role in the pathogeneis of other neuropsychiatric disorders.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15247538",
                    "offsetInBeginSection": 652,
                    "offsetInEndSection": 753,
                    "text": "There is initial evidence suggesting the beneficial effect of immunosuppression in Sydenham's chorea.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15377732",
                    "offsetInBeginSection": 288,
                    "offsetInEndSection": 603,
                    "text": "Brain tissue-specific antibodies have been demonstrated in a subset of children with Sydenham chorea (a component of the Jones criteria for the diagnosis of rheumatic fever), and most Sydenham chorea patients manifest obsessive-compulsive symptoms very similar to those in traditional obsessive-compulsive disorder.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the cause of Sydenham's chorea?",
            "type": "summary",
            "id": "660c06b8fdcbea915f00002e",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37130369",
                "http://www.ncbi.nlm.nih.gov/pubmed/30466724",
                "http://www.ncbi.nlm.nih.gov/pubmed/36032640",
                "http://www.ncbi.nlm.nih.gov/pubmed/33959220",
                "http://www.ncbi.nlm.nih.gov/pubmed/35533063",
                "http://www.ncbi.nlm.nih.gov/pubmed/34039511",
                "http://www.ncbi.nlm.nih.gov/pubmed/34414505",
                "http://www.ncbi.nlm.nih.gov/pubmed/33410651",
                "http://www.ncbi.nlm.nih.gov/pubmed/36428501",
                "http://www.ncbi.nlm.nih.gov/pubmed/34017878"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37130369",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 258,
                    "text": "Orthobiologic agents, including platelet-rich plasma, connective tissue progenitor cells derived from bone marrow, adipose, and other tissues, and purified cytokines and small peptides, have tremendous potential to target deficiencies in soft-tissue healing.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30466724",
                    "offsetInBeginSection": 123,
                    "offsetInEndSection": 395,
                    "text": "These substances include bone autograft, bone allograft, demineralized bone matrix, bone graft substitutes, bone marrow aspirate concentrate, platelet-rich plasma, bone morphogenetic proteins, platelet-derived growth factor, parathyroid hormone, and vitamin D and calcium.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36032640",
                    "offsetInBeginSection": 524,
                    "offsetInEndSection": 848,
                    "text": "The fundamental orthobiologics today ready for use in Orthopedic Surgery are the following: osseous hollow fillers, extracellular matrix (ECM) substances, platelet-rich plasma (PRP), bone morphogenetic protein-2 (BMP-2), bone marrow aspirate (BMA), bone marrow aspirate concentrate (BMAC), and mesenchymal stem cells (MSCs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33959220",
                    "offsetInBeginSection": 218,
                    "offsetInEndSection": 369,
                    "text": "The orthobiologics included in this article are hyaluronic acid, platelet rich plasma, bone marrow, adipose tissue and expanded mesenchymal stem cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35533063",
                    "offsetInBeginSection": 634,
                    "offsetInEndSection": 829,
                    "text": "Currently studied orthobiologics include autologous and allogenic cell therapies, autologous blood products, hyaluronic acid, gene therapies, Wnt inhibitors, and a variety of systemic treatments.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34039511",
                    "offsetInBeginSection": 792,
                    "offsetInEndSection": 933,
                    "text": "Ten studies compared autologous bone graft versus no graft and 2 compared remote versus local graft with few studies of other orthobiologics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34039511",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "Orthobiologics are biologically-derived materials intended to promote bone formation and union.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34414505",
                    "offsetInBeginSection": 1051,
                    "offsetInEndSection": 1162,
                    "text": "Of the physicians that used orthobiologics, the most used hyaluronic acid (76%) and platelet-rich plasma (27%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33410651",
                    "offsetInBeginSection": 922,
                    "offsetInEndSection": 1028,
                    "text": "Orthobiologic users reported the following: 71.6% are increasing their use, and 23.9% advertise their use.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33410651",
                    "offsetInBeginSection": 1296,
                    "offsetInEndSection": 1512,
                    "text": "Leukocyte-rich platelet-rich plasma is the most popular orthobiologic in muscle, ligament, tendon, and labral injuries, whereas bone marrow aspirate concentrate is most popular for focal articular cartilage injuries.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Please list sources of orthobiologics",
            "type": "list",
            "id": "66088b42fdcbea915f000009",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29483208",
                "http://www.ncbi.nlm.nih.gov/pubmed/29077941",
                "http://www.ncbi.nlm.nih.gov/pubmed/33601293",
                "http://www.ncbi.nlm.nih.gov/pubmed/31747009",
                "http://www.ncbi.nlm.nih.gov/pubmed/35849035",
                "http://www.ncbi.nlm.nih.gov/pubmed/32642719",
                "http://www.ncbi.nlm.nih.gov/pubmed/33517558",
                "http://www.ncbi.nlm.nih.gov/pubmed/34549181",
                "http://www.ncbi.nlm.nih.gov/pubmed/29075855",
                "http://www.ncbi.nlm.nih.gov/pubmed/36071925"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29483208",
                    "offsetInBeginSection": 188,
                    "offsetInEndSection": 386,
                    "text": "Depatux-m has demonstrated promising clinical activity in glioblastoma multiforme (GBM) patients and is currently being evaluated in clinical trials in first-line and recurrent GBM disease settings.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29077941",
                    "offsetInBeginSection": 1430,
                    "offsetInEndSection": 1560,
                    "text": "Depatux-m alone or in combination with temozolomide demonstrated an acceptable safety and pharmacokinetic profile in glioblastoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33601293",
                    "offsetInBeginSection": 1141,
                    "offsetInEndSection": 1315,
                    "text": "Depatux-M had no impact on HRQoL and NDFS in patients with EGFR-amplified recurrent glioblastoma, except for more visual disorders, an expected side-effect of the study drug.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31747009",
                    "offsetInBeginSection": 1486,
                    "offsetInEndSection": 1720,
                    "text": "This trial suggests a possible role for the use of Depatux-M in combination with temozolomide in EGFR amplified recurrent glioblastoma, especially in patients relapsing well after the end of first-line adjuvant temozolomide treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35849035",
                    "offsetInBeginSection": 945,
                    "offsetInEndSection": 1104,
                    "text": "Prespecified interim analysis found no improvement in OS for depatux-m over placebo (median 18.9 vs. 18.7 months, HR 1.02, 95% CI 0.82-1.26, 1-sided p = 0.63).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32642719",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 267,
                    "text": "The randomized phase II INTELLANCE-2/EORTC_1410 trial on EGFR-amplified recurrent glioblastomas showed a trend towards improved overall survival when patients were treated with depatux-m plus temozolomide compared with the control arm of alkylating chemotherapy only.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35849035",
                    "offsetInBeginSection": 1598,
                    "offsetInEndSection": 1697,
                    "text": "Interim analysis demonstrated no OS benefit for depatux-m in treating EGFR-amp newly diagnosed GBM.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33517558",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 229,
                    "text": "Depatux-m is an antibody drug conjugate (ADC) that targets and inhibits growth of cancer cells overexpressing the epidermal growth factor receptor (EGFR) or the 2-7 deletion mutant (EGFRvIII) in tumor models in vitro and in vivo.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34549181",
                    "offsetInBeginSection": 619,
                    "offsetInEndSection": 752,
                    "text": "Both preclinical and clinical data showed intra-tumoral concentration and efficacy of Depatux-m inversely correlated with tumor size.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29483208",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 187,
                    "text": "Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR antibody ABT-806 and the monomethyl auristatin F (MMAF) warhead.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Depatuxizumab mafodotin effective for glioblastoma?",
            "type": "yesno",
            "id": "65d132101930410b13000035",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/8588329"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8588329",
                    "offsetInBeginSection": 271,
                    "offsetInEndSection": 364,
                    "text": "Modified live viral vaccines, as used for more than thirty years, have proved very effective.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "List of attenuated viral vaccines still in use.",
            "type": "list",
            "id": "660d2299fdcbea915f000038",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33212887",
                "http://www.ncbi.nlm.nih.gov/pubmed/24985542",
                "http://www.ncbi.nlm.nih.gov/pubmed/24647390",
                "http://www.ncbi.nlm.nih.gov/pubmed/17963270",
                "http://www.ncbi.nlm.nih.gov/pubmed/30813413",
                "http://www.ncbi.nlm.nih.gov/pubmed/32879053",
                "http://www.ncbi.nlm.nih.gov/pubmed/37960352",
                "http://www.ncbi.nlm.nih.gov/pubmed/34298902",
                "http://www.ncbi.nlm.nih.gov/pubmed/34114759",
                "http://www.ncbi.nlm.nih.gov/pubmed/32468981"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33212887",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "text": "One-carbon (1C) metabolism is a metabolic network that is centered on folate, a B vitamin; it integrates nutritional signals with biosynthesis, redox homeostasis, and epigenetics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24985542",
                    "offsetInBeginSection": 480,
                    "offsetInEndSection": 591,
                    "text": "Recent research reveals a role for mitochondrial folate-dependent one-carbon metabolism in neural tube closure.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24647390",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "Folate-mediated one-carbon metabolism is essential for DNA synthesis, repair, and methylation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17963270",
                    "offsetInBeginSection": 507,
                    "offsetInEndSection": 661,
                    "text": "Folate-mediated one-carbon metabolism (OCM) is essential for de novo nucleotide biosynthesis, methionine biosynthesis, and cellular methylation reactions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30813413",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Vitamins B9 (folate) and B12 act as methyl donors in the one-carbon metabolism which influences epigenetic mechanisms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32879053",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "text": "One-carbon (1C) metabolism encompasses folate-mediated 1C transfer reactions and related processes, including nucleotide and amino acid biosynthesis, antioxidant regeneration, and epigenetic regulation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37960352",
                    "offsetInBeginSection": 189,
                    "offsetInEndSection": 353,
                    "text": "While folate plays a pivotal role in the one-carbon cycle, which is essential for DNA synthesis, repair, and methylation, concerns arise about its excessive intake.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34298902",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "One-carbon (1C) metabolism plays a key role in biological functions linked to the folate cycle.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17963270",
                    "offsetInBeginSection": 377,
                    "offsetInEndSection": 506,
                    "text": "accumulating evidence from population-based studies has demonstrated that folate status is a significant determinant of NTD risk.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24647390",
                    "offsetInBeginSection": 1910,
                    "offsetInEndSection": 2000,
                    "text": "Biomarkers of inflammation are associated with PLP, RBC folate, and homocysteine in women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is One-carbon (1C)  metabolism associated with folate?",
            "type": "yesno",
            "id": "66081d61fdcbea915f000007",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33722875",
                "http://www.ncbi.nlm.nih.gov/pubmed/24708011",
                "http://www.ncbi.nlm.nih.gov/pubmed/37314244"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33722875",
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 797,
                    "text": "The Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH-Trauma study) is comparing TXA, initiated prehospital and continued in hospital over 8 hours, with placebo in patients with severe trauma at risk of acute traumatic coagulopathy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24708011",
                    "offsetInBeginSection": 474,
                    "offsetInEndSection": 762,
                    "text": "The Pre-hospital Antifibrinolytics for Traumatic Coagulopathy and Haemorrhage (PATCH)-Trauma study is a National Health and Medical Research Council-funded randomised controlled trial of early administration of TxA in severely injured patients likely to have acute traumatic coagulopathy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37314244",
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 567,
                    "text": "We randomly assigned adults with major trauma who were at risk for trauma-induced coagulopathy to receive tranexamic acid (administered intravenously as a bolus dose of 1 g before hospital admission, followed by a 1-g infusion over a period of 8 hours after arrival at the hospital) or matched placebo.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What was tested in the PATCH-Trauma trial?",
            "type": "summary",
            "id": "65cfd9071930410b13000024",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16724868",
                "http://www.ncbi.nlm.nih.gov/pubmed/15828549",
                "http://www.ncbi.nlm.nih.gov/pubmed/20087037",
                "http://www.ncbi.nlm.nih.gov/pubmed/23749885",
                "http://www.ncbi.nlm.nih.gov/pubmed/33790174",
                "http://www.ncbi.nlm.nih.gov/pubmed/21768793",
                "http://www.ncbi.nlm.nih.gov/pubmed/36388681",
                "http://www.ncbi.nlm.nih.gov/pubmed/24393993",
                "http://www.ncbi.nlm.nih.gov/pubmed/15187215",
                "http://www.ncbi.nlm.nih.gov/pubmed/15495753"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16724868",
                    "offsetInBeginSection": 426,
                    "offsetInEndSection": 695,
                    "text": "In the second-line treatment of advanced colorectal cancer, patients who received bevacizumab in combination with a fluorouracil/leucovorin plus oxaliplatin (FOLFOX4) regimen had an overall survival time that was 2 months longer than that in patients receiving FOLFOX4.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15828549",
                    "offsetInBeginSection": 259,
                    "offsetInEndSection": 437,
                    "text": "In combination with fluorouracil (5-FU)-based chemotherapy, this agent significantly prolongs overall and progression-free survival of patients with metastatic colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20087037",
                    "offsetInBeginSection": 869,
                    "offsetInEndSection": 1035,
                    "text": "In combination therapy of Bevacizumab and mFOLFOX6, the TTP of Bevacizumab first-line treatment was significantly longer than that of second-line treatment (p<0. 05).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23749885",
                    "offsetInBeginSection": 223,
                    "offsetInEndSection": 598,
                    "text": "Benefit of adding bevacizumab to second-line regimen after failing a bevacizumab-containing regimen, or aflibercept plus FOLFIRI) (irinotecan, 5-FU and leucovorin) after failing first-line oxaliplatin regimen with or without bevacizumab or regorafenib as a salvage therapy, do indicate the addiction to anti-vascular endothelial growth factor (VEGF) agents in these patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33790174",
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 324,
                    "text": "Some studies have reported that administration of TAS-102 concomitant with bevacizumab prolongs progression-free and overall survival in colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33790174",
                    "offsetInBeginSection": 681,
                    "offsetInEndSection": 802,
                    "text": "Combination therapy using TAS-102 and bevacizumab is a feasible Late-line chemotherapeutic regimen for colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21768793",
                    "offsetInBeginSection": 484,
                    "offsetInEndSection": 705,
                    "text": "Bevacizumab may be added to first, second and third-line chemotherapy for palliative treatment of metastatic colorectal cancer, and data indicate an increase in patient survival with a good response rate and low toxicity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36388681",
                    "offsetInBeginSection": 1880,
                    "offsetInEndSection": 1974,
                    "text": "Postoperative chemotherapy involved 4 cycles of bevacizumab with capecitabine and oxaliplatin.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24393993",
                    "offsetInBeginSection": 403,
                    "offsetInEndSection": 573,
                    "text": "After 6 courses, hepatic metastasis from colon cancer recurred. Thus, primary treatment with SOX plus bevacizumab for advanced metastatic colorectal cancer was initiated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24393993",
                    "offsetInBeginSection": 574,
                    "offsetInEndSection": 778,
                    "text": "However, progressive disease was diagnosed after 10 postoperative courses of chemotherapy, and therefore, chemotherapy with irinotecan and S-1 (IRIS) plus panitumumab was initiated as secondary treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is the use of Bevacizumab indicated after progression to a previous regimen with Bevacizumab in advanced colorectal cancer patients?",
            "type": "yesno",
            "id": "66099af7fdcbea915f000020",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30102754",
                "http://www.ncbi.nlm.nih.gov/pubmed/36681385",
                "http://www.ncbi.nlm.nih.gov/pubmed/2900797",
                "http://www.ncbi.nlm.nih.gov/pubmed/32855778",
                "http://www.ncbi.nlm.nih.gov/pubmed/3303067",
                "http://www.ncbi.nlm.nih.gov/pubmed/23757196",
                "http://www.ncbi.nlm.nih.gov/pubmed/2029017",
                "http://www.ncbi.nlm.nih.gov/pubmed/20469001",
                "http://www.ncbi.nlm.nih.gov/pubmed/11268765",
                "http://www.ncbi.nlm.nih.gov/pubmed/11800539"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30102754",
                    "offsetInBeginSection": 365,
                    "offsetInEndSection": 444,
                    "text": "For ADHD, stimulants and nonstimulants can be used as first-line interventions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30102754",
                    "offsetInBeginSection": 445,
                    "offsetInEndSection": 570,
                    "text": "For anxiety and depression, selective serotonin reuptake inhibitors are well-established treatments and often well-tolerated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36681385",
                    "offsetInBeginSection": 788,
                    "offsetInEndSection": 964,
                    "text": "Antipsychotics were the most frequently prescribed class of psychotropic drugs (89%), followed by antiepileptics/mood stabilizers/lithium (42.1%) and anxiolytics (BDZ) (38.5%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2900797",
                    "offsetInBeginSection": 197,
                    "offsetInEndSection": 376,
                    "text": "Management of elderly patients with agitation, psychosis, anxiety, and insomnia are reviewed with a discussion of the optimal use of antipsychotic, anxiolytic, and sedating drugs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32855778",
                    "offsetInBeginSection": 412,
                    "offsetInEndSection": 643,
                    "text": "This review comprehensively summarizes the current literature on DDIs between antiretroviral drugs and chloroquine/hydroxychloroquine, and psychotropics, including antidepressants, antipsychotics, mood stabilizers, and anxiolytics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3303067",
                    "offsetInBeginSection": 345,
                    "offsetInEndSection": 483,
                    "text": "As there is still insufficient evidence to prove the safeness of other psychoactive drugs for the fetus, caution seems warranted here too.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23757196",
                    "offsetInBeginSection": 1116,
                    "offsetInEndSection": 1234,
                    "text": "These focused mainly on stimulants, central sympatholytics (such as clonidine), antipsychotics and 'mood stabilizers'.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2029017",
                    "offsetInBeginSection": 762,
                    "offsetInEndSection": 997,
                    "text": "Psychoactive drugs were used in 89% of the cases. Anxiolytics accounted for 49% of the psychoactive prescriptions, and hypnotics made up 43% of these prescriptions. The five most frequently used psychoactive drugs were benzodiazepines.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20469001",
                    "offsetInBeginSection": 155,
                    "offsetInEndSection": 320,
                    "text": "Particular attention is granted the anxiolytic agents, antidepressants, and neuroleptic drugs, and the related psychiatric conditions are considered correspondingly.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11268765",
                    "offsetInBeginSection": 774,
                    "offsetInEndSection": 849,
                    "text": "The use of psychotropic drugs is often required and thus cannot be ignored.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Please list the psychoactive drugs used to treat mental health disorders.",
            "type": "list",
            "id": "65f48fa2c4010b4d7800000f",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16500912",
                "http://www.ncbi.nlm.nih.gov/pubmed/16750332",
                "http://www.ncbi.nlm.nih.gov/pubmed/16979839",
                "http://www.ncbi.nlm.nih.gov/pubmed/17385825",
                "http://www.ncbi.nlm.nih.gov/pubmed/28763330",
                "http://www.ncbi.nlm.nih.gov/pubmed/23587311",
                "http://www.ncbi.nlm.nih.gov/pubmed/17762432",
                "http://www.ncbi.nlm.nih.gov/pubmed/31217818",
                "http://www.ncbi.nlm.nih.gov/pubmed/22855141",
                "http://www.ncbi.nlm.nih.gov/pubmed/32695890"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16500912",
                    "offsetInBeginSection": 653,
                    "offsetInEndSection": 1018,
                    "text": "Continuous oral administration of capecitabine (825 mg/m(2) twice daily for 7 days/week) is an effective regimen and has similar tolerability to the less dose-intensive intermittent regimens of capecitabine given 5 days/week followed by 2 day's rest or 14 days followed by 7 day's rest as used in systemic chemotherapy for patients with colorectal or breast cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16750332",
                    "offsetInBeginSection": 1481,
                    "offsetInEndSection": 1642,
                    "text": "Capecitabine 725 mg/m2 p.o., twice daily in combination with oxaliplatin 50 mg/m2/week and RT 50.4 Gy in 28 fractions is the recommended dose for future studies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16979839",
                    "offsetInBeginSection": 549,
                    "offsetInEndSection": 689,
                    "text": "dose level II, irinotecan 40 mg/m(2) and capecitabine 1000 mg/m(2); and dose level III, irinotecan 50 mg/m(2) and capecitabine 1000 mg/m(2).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17385825",
                    "offsetInBeginSection": 418,
                    "offsetInEndSection": 542,
                    "text": "Capecitabine was administered orally at a dose of 825 mg/m(2) twice-daily concomitantly every day during pelvic irradiation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28763330",
                    "offsetInBeginSection": 607,
                    "offsetInEndSection": 756,
                    "text": "In general, bavituximab was safe and well tolerated in combination with radiation therapy and capecitabine in the treatment of rectal adenocarcinoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23587311",
                    "offsetInBeginSection": 514,
                    "offsetInEndSection": 725,
                    "text": "Patients received conventionally fractionated radiotherapy (50.4 Gy in 1.8 Gy fractions) and simultaneous chemotherapy with capecitabine 825 mg/m2 bid (d1-14, d22-35) and oxaliplatin 50 mg/m2 (d1, d8, d22, d29).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17762432",
                    "offsetInBeginSection": 178,
                    "offsetInEndSection": 366,
                    "text": "Patients with adenocarcinoma of the rectum stage >or=T3 or >or=N1 were treated with capecitabine 1330 mg/m per day in 2 divided doses days 1 to 42 and 50.4 Gy of RT in 28 1.8-Gy fractions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31217818",
                    "offsetInBeginSection": 416,
                    "offsetInEndSection": 597,
                    "text": "Concurrently, irinotecan of 80 mg/m All patients completed capecitabine-based radiotherapy as scheduled, and 42 (81%) patients completed more than three cycles of weekly irinotecan.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22855141",
                    "offsetInBeginSection": 319,
                    "offsetInEndSection": 491,
                    "text": "Capecitabine was administered at 825 mg/m(2) twice daily for 5 days/week and oxaliplatin at 50 mg/m(2) on day 1 weekly for 5 weeks starting the first day of RT (before RT).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32695890",
                    "offsetInBeginSection": 558,
                    "offsetInEndSection": 650,
                    "text": "Treatment protocol combined CXB (80-110 Gy/3-4 fractions) and EBRT  concurrent capecitabine.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients?",
            "type": "factoid",
            "id": "66099c01fdcbea915f000023",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24222823",
                "http://www.ncbi.nlm.nih.gov/pubmed/26323740",
                "http://www.ncbi.nlm.nih.gov/pubmed/26164346",
                "http://www.ncbi.nlm.nih.gov/pubmed/22942784",
                "http://www.ncbi.nlm.nih.gov/pubmed/27739268",
                "http://www.ncbi.nlm.nih.gov/pubmed/31423403",
                "http://www.ncbi.nlm.nih.gov/pubmed/35308754",
                "http://www.ncbi.nlm.nih.gov/pubmed/30449379",
                "http://www.ncbi.nlm.nih.gov/pubmed/34997877",
                "http://www.ncbi.nlm.nih.gov/pubmed/37577868"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24222823",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 275,
                    "text": "Tako-Tsubo syndrome (TS) is a still rarely diagnosed clinical syndrome, which is characterized by acute onset of chest pain, transient cardiac dysfunction with (frequently) reversible wall motion abnormalities (WMAs), but with no relevant obstructive coronary artery disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26323740",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 215,
                    "text": "Takotsubo cardiomyopathy, also known as broken heart syndrome is a stress-induced cardiomyopathy, which can be interpreted as an acute coronary syndrome as it progresses with suggestive electrocardiographic changes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26164346",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 215,
                    "text": "Takotsubo cardiomyopathy, also known as broken heart syndrome is a stress-induced cardiomyopathy, which can be interpreted as an acute coronary syndrome as it progresses with suggestive electrocardiographic changes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22942784",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "The Tako-Tsubo syndrome is a reversible form of an acute stress-related cardiomyopathy that was reported during the last decade.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27739268",
                    "offsetInBeginSection": 763,
                    "offsetInEndSection": 845,
                    "text": "This syndrome has characteristic reversible left ventricular systolic dysfunction.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31423403",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "text": "Takotsubo cardiomyopathy (TTC) is reversible stress-induced cardiomyopathy featuring symptoms of acute myocardial infarction without significant coronary artery abnormalities.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35308754",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "text": "Stress-induced cardiomyopathy (SIC), or Takotsubo syndrome, is considered a reversible dysfunction of the left ventricle that may mimic an acute coronary syndrome (ACS).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30449379",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 212,
                    "text": "Stress-induced cardiomyopathy is characterized by reversible myocardial injury with distinctive regional wall motion abnormalities of the left ventricle, usually precipitated by an emotional or physical stressor.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34997877",
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 303,
                    "text": "Both are characterized by left ventricular systolic dysfunction. However, this dysfunction is reversible in the majority of TTS patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37577868",
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 306,
                    "text": "Perhaps what is of most significance is the reversible nature of TTS, with many patients achieving recovery within a few weeks to months.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Tako-Tsubo syndrome is an irreversible form of an acute stress-related cardiomyopathy?",
            "type": "yesno",
            "id": "6609827afdcbea915f000011",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [],
            "snippets": [],
            "body": "Should PDYD polymorphism determination be routinely performed in patients with colorectal cancer patients?",
            "type": "yesno",
            "id": "65f77596c4010b4d7800002c",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27186101",
                "http://www.ncbi.nlm.nih.gov/pubmed/27113601",
                "http://www.ncbi.nlm.nih.gov/pubmed/17607185",
                "http://www.ncbi.nlm.nih.gov/pubmed/31885862",
                "http://www.ncbi.nlm.nih.gov/pubmed/15865887",
                "http://www.ncbi.nlm.nih.gov/pubmed/18256986",
                "http://www.ncbi.nlm.nih.gov/pubmed/35019387",
                "http://www.ncbi.nlm.nih.gov/pubmed/19016573",
                "http://www.ncbi.nlm.nih.gov/pubmed/25826609",
                "http://www.ncbi.nlm.nih.gov/pubmed/16355314"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27186101",
                    "offsetInBeginSection": 703,
                    "offsetInEndSection": 846,
                    "text": "A better understanding of the molecular and cellular components of the immunopathogenesis of MS is allowing the development of novel therapies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27186101",
                    "offsetInBeginSection": 507,
                    "offsetInEndSection": 702,
                    "text": "Recent evidence, however, suggests that other immune cells including TH17 cells, CD8+ effector T cells, CD4+ CD25+ regulatory T cells, and B cells may play a prominent role in MS immunopathology.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27113601",
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 190,
                    "text": "Significant progress has been made in understanding the genetics and pathogenesis of MS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27113601",
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 298,
                    "text": "The classification of MS phenotypes has been revised and the landscape of therapeutics is rapidly evolving.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17607185",
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 212,
                    "text": "Details of the inflammatory response as well as mechanisms of demyelination were elucidated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31885862",
                    "offsetInBeginSection": 255,
                    "offsetInEndSection": 456,
                    "text": "A large body of research on the immunobiology of MS has resulted in a variety of anti-inflammatory therapies that are highly effective at reducing brain inflammation and clinical/radiological relapses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31885862",
                    "offsetInBeginSection": 457,
                    "offsetInEndSection": 698,
                    "text": "However, despite potent suppression of inflammation, benefit in the more important and disabling progressive phase is extremely limited; thus, progressive MS has emerged as the greatest challenge for the MS research and clinical communities.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15865887",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "text": "Neuroimaging studies continue to provide important insights into the central nervous system disease pathology of multiple sclerosis (MS).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15865887",
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 393,
                    "text": "Although conventional magnetic resonance imaging remains the mainstay of diagnosis and laboratory assessment of therapeutic response in MS, quantitative techniques continue to extend our understanding of both macroscopic and microscopic disease processes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18256986",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "Conventional magnetic resonance imaging (MRI) is sensitive in detecting abnormalities in multiple sclerosis (MS), but these tend not to be pathologically specific.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "New treatments in multiple sclerosis.",
            "type": "list",
            "id": "660d7491fdcbea915f000041",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27722180",
                "http://www.ncbi.nlm.nih.gov/pubmed/23403257",
                "http://www.ncbi.nlm.nih.gov/pubmed/16386929",
                "http://www.ncbi.nlm.nih.gov/pubmed/22765254",
                "http://www.ncbi.nlm.nih.gov/pubmed/25315738",
                "http://www.ncbi.nlm.nih.gov/pubmed/21319362",
                "http://www.ncbi.nlm.nih.gov/pubmed/34807779",
                "http://www.ncbi.nlm.nih.gov/pubmed/23461146",
                "http://www.ncbi.nlm.nih.gov/pubmed/29448836",
                "http://www.ncbi.nlm.nih.gov/pubmed/26250421"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27722180",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "Crigler-Najjar syndrome is a severe metabolic disease of the liver due to a reduced activity of the UDP Glucuronosyltransferase 1A1 (UGT1A1) enzyme.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23403257",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "UGT1A1 enzyme defects are responsible of both Gilbert syndrome (GS) and Crigler-Najjar syndrome (CNS).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16386929",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "text": "Gilbert and Crigler-Najjar syndromes are familial unconjugated hyperbilirubinemias caused by genetic lesions involving a single complex locus encoding for bilirubin UDP-glucuronosyltransferase (UGT1A1) gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22765254",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 210,
                    "text": "Crigler-Najjar syndrome is an autosomal recessive disorder with severe unconjugated hyperbilirubinemia due to deficiency of bilirubin UDP-glucuronosyltransferase isozyme 1A1 (UGT1A1) encoded by the UGT1A1 gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25315738",
                    "offsetInBeginSection": 1142,
                    "offsetInEndSection": 1353,
                    "text": "Crigler-Najjar syndrome is the severe inherited form of unconjugated hyperbilirubinaemia due to mutations in the UGT1A1 gene, which can cause kernicterus early in life and can be even lethal when left untreated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21319362",
                    "offsetInBeginSection": 490,
                    "offsetInEndSection": 677,
                    "text": "Sequence analysis of the UGT1A1 gene revealed that she was a compound heterozygote with p.[G71R; Y486D] + [Y486D] mutations, which suggests Crigler-Najjar syndrome type II rather than GS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34807779",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 301,
                    "text": "Inactivation and very low activity of UGT1A1 in the liver can be fatal or lead to lifelong Gilbert's syndrome (GS) and Crigler-Najjar syndrome (CN).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23461146",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 334,
                    "text": "The UDP-glucuronosyltransferase 1A1 gene that encode the enzyme UGT1A1 responsible for glucuronidation undergoes several variations that may affect the enzymatic activity or expression and which are the cause of metabolic disorders related to the glucuronidation of bilirubin, such as Gilbert's syndrome and Crigler Najjar's syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29448836",
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 386,
                    "text": "Crigler-Najjar syndrome is an autosomal recessive disorder of bilirubin metabolism that occurs when the liver's uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) enzyme activity is partially or completely absent.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26250421",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 253,
                    "text": "Hereditary unconjugated hyperbilirubinemias, Crigler-Najjar syndrome type I, Crigler-Najjar syndrome type II (CN-2), and Gilbert syndrome (GS) all result from mutations of the bilirubin uridine 5'-diphosphate (UDP)-glucuronosyltransferase gene (UGT1A1).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is UGT1A1 implicated in Criglerâ€“Najjar syndrome?",
            "type": "yesno",
            "id": "65cfcc8f1930410b13000018",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30741605",
                "http://www.ncbi.nlm.nih.gov/pubmed/29706033",
                "http://www.ncbi.nlm.nih.gov/pubmed/34097159",
                "http://www.ncbi.nlm.nih.gov/pubmed/28524897",
                "http://www.ncbi.nlm.nih.gov/pubmed/36789830",
                "http://www.ncbi.nlm.nih.gov/pubmed/37114110",
                "http://www.ncbi.nlm.nih.gov/pubmed/29922963",
                "http://www.ncbi.nlm.nih.gov/pubmed/30680866",
                "http://www.ncbi.nlm.nih.gov/pubmed/33394166",
                "http://www.ncbi.nlm.nih.gov/pubmed/34157213"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30741605",
                    "offsetInBeginSection": 765,
                    "offsetInEndSection": 974,
                    "text": "As providers are caring for transgender patients, it is imperative to understand where a patient is in their gender transition and how hormonal and/or surgical therapies affect their cancer risk and screening.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29706033",
                    "offsetInBeginSection": 1405,
                    "offsetInEndSection": 1560,
                    "text": "Gender-affirming hormones have not been shown to affect cancer risk, but there is a clear need for well-designed, robust studies to confirm or refute this.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34097159",
                    "offsetInBeginSection": 298,
                    "offsetInEndSection": 537,
                    "text": "The rate of breast cancer development in transgender individuals differs from rates observed in their cisgender counterparts, however there is little evidence to quantify these differences and guide evidence-based screening and prevention.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28524897",
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 286,
                    "text": "The purpose of this article is to summarize breast cancer risk assessment and screening recommendations for transgender individuals.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34097159",
                    "offsetInBeginSection": 624,
                    "offsetInEndSection": 819,
                    "text": "In this review, we discuss barriers to equitable breast cancer care, risk factors for breast cancer development, and existing data to support breast cancer screening in transgender men and women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36789830",
                    "offsetInBeginSection": 559,
                    "offsetInEndSection": 808,
                    "text": "FtM individuals had a higher risk of developing breast cancer in comparison to cisgender men [standardized incidence ratio (SIR) = 63.4; 95% confidence interval (CI), 32.2-124.9] but a lower risk than cisgender women (SIR = 0.42; 95% CI, 0.07-2.41).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36789830",
                    "offsetInBeginSection": 809,
                    "offsetInEndSection": 1018,
                    "text": "Similarly, MtF individuals were at higher risk of developing breast cancer in comparison to cisgender men (SIR = 22.5; 95% CI, 5.54-91.8) and at lower risk than cisgender women (SIR = 0.30; 95% CI, 0.22-0.42).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37114110",
                    "offsetInBeginSection": 1036,
                    "offsetInEndSection": 1179,
                    "text": "Evidence on rates of breast cancer screening among transgender people and the association between GAHT and breast cancer risk was inconclusive.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37114110",
                    "offsetInBeginSection": 1180,
                    "offsetInEndSection": 1350,
                    "text": "Factors negatively associated with cancer screening behaviors included socioeconomic barriers, stigma, and lack of health provider awareness of transgender health issues.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29922963",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "text": "High quality empirical data assessing morbidity and mortality and cancer incidence among transgender people are almost non-existent.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Cancer risk in transgender individuals.",
            "type": "summary",
            "id": "660d70b3fdcbea915f00003f",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36974796",
                "http://www.ncbi.nlm.nih.gov/pubmed/32307874",
                "http://www.ncbi.nlm.nih.gov/pubmed/35534342",
                "http://www.ncbi.nlm.nih.gov/pubmed/36291850",
                "http://www.ncbi.nlm.nih.gov/pubmed/38075390",
                "http://www.ncbi.nlm.nih.gov/pubmed/36103864",
                "http://www.ncbi.nlm.nih.gov/pubmed/35785525"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36974796",
                    "offsetInBeginSection": 1067,
                    "offsetInEndSection": 1212,
                    "text": "Lenvatinib might be useful for intermediate and advanced HCC and long-term survival may be obtained by combining lenvatinib therapy with surgery.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32307874",
                    "offsetInBeginSection": 1443,
                    "offsetInEndSection": 1584,
                    "text": "More patients treated with lenvatinib for advanced HCC maintained their liver functional reserves compared with those treated with sorafenib.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32307874",
                    "offsetInBeginSection": 1585,
                    "offsetInEndSection": 1688,
                    "text": "Maintaining the liver functional reserve contributed to better outcomes for patients with advanced HCC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35534342",
                    "offsetInBeginSection": 1535,
                    "offsetInEndSection": 1673,
                    "text": "Only in the high-risk group, we found that lenvatinib significantly improved prognosis compared with that of the control group (P < 0.05).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36291850",
                    "offsetInBeginSection": 396,
                    "offsetInEndSection": 640,
                    "text": "In this study, the efficacy of lenvatinib and its combination with TACE after lenvatinib was investigated in 140 patients with intermediate-stage u-HCC treated with lenvatinib mainly because of being judged to be TACE-refractory or -unsuitable.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36291850",
                    "offsetInBeginSection": 1003,
                    "offsetInEndSection": 1159,
                    "text": "While 95% of all patients were TACE-refractory or -unsuitable, the further prognosis was prolonged by the combination with TACE after lenvatinib initiation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38075390",
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 444,
                    "text": "While recommended standard treatment for patients with advanced HCC is systemic therapy, various treatment approaches, including resection, transarterial chemoembolization, and radiation, have been empirically suggested to improve prognosis by eliminating or controlling MVI.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36103864",
                    "offsetInBeginSection": 1526,
                    "offsetInEndSection": 1626,
                    "text": "Due to the antiangiogenic effect of lenvatinib, a shrinkage in the TBV diameter of HCC was observed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36103864",
                    "offsetInBeginSection": 1627,
                    "offsetInEndSection": 1702,
                    "text": "The shrinkage of TBV may be regarded as a process of normalization of TBVs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36103864",
                    "offsetInBeginSection": 1703,
                    "offsetInEndSection": 1835,
                    "text": "The shrinkage of TBVs in imaging analysis may be associated with improved prognosis; however, additional studies are still required.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Does Lenvatinib plus pembrolizumab improve prognosis of advanced hepatocellular carcinoma?",
            "type": "yesno",
            "id": "65d372231930410b13000047",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22196327",
                "http://www.ncbi.nlm.nih.gov/pubmed/37046053",
                "http://www.ncbi.nlm.nih.gov/pubmed/32620897",
                "http://www.ncbi.nlm.nih.gov/pubmed/24904279",
                "http://www.ncbi.nlm.nih.gov/pubmed/24639627",
                "http://www.ncbi.nlm.nih.gov/pubmed/32494638",
                "http://www.ncbi.nlm.nih.gov/pubmed/28634443",
                "http://www.ncbi.nlm.nih.gov/pubmed/29610177",
                "http://www.ncbi.nlm.nih.gov/pubmed/37640554",
                "http://www.ncbi.nlm.nih.gov/pubmed/26134120"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22196327",
                    "offsetInBeginSection": 219,
                    "offsetInEndSection": 344,
                    "text": "Recent findings suggest that NALCN, in association with UNC79 and UNC80, contributes a basal Na+ leak conductance in neurons.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37046053",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "text": "The sodium leak channel (NALCN) gene encodes a sodium leak channel that plays an important role in the regulation of the resting membrane potential and the control of neuronal excitability.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32620897",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "The sodium-leak channel NALCN forms a subthreshold sodium conductance that controls the resting membrane potentials of neurons.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24904279",
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 459,
                    "text": "NALCN is part of a complex that includes not only GPCRs, but also UNC-79, UNC-80, NLF-1 and src family of Tyrosine kinases (SFKs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24639627",
                    "offsetInBeginSection": 104,
                    "offsetInEndSection": 233,
                    "text": "Sodium leak channels (NALCN) play a key role in rhythmic behaviors by helping set, or subtly changing neuronal resting potential.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24639627",
                    "offsetInBeginSection": 334,
                    "offsetInEndSection": 480,
                    "text": "NALCN channels can associate with numerous subunits in different tissues and can be activated by several different peptides and second messengers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32494638",
                    "offsetInBeginSection": 242,
                    "offsetInEndSection": 363,
                    "text": "Here, we found that robust function of NALCN in heterologous systems requires co-expression of UNC79, UNC80, and FAM155A.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634443",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "The sodium leak channel NARROW ABDOMEN (NA)/ NALCN is an important component of circadian pacemaker neuronal output.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29610177",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 254,
                    "text": "The sodium leak channel nonselective protein (NALCN) is a regulator of the pacemaker neurons that are responsible for rhythmic behavior (including respiration), maintaining the resting membrane potential, and are required for action potential production.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37640554",
                    "offsetInBeginSection": 1531,
                    "offsetInEndSection": 1617,
                    "text": "NALCN makes substantial contributions to driving pacemaking in VTA DAN subpopulations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the function of the sodium leak channel (NALCN)?",
            "type": "summary",
            "id": "660710b7fdcbea915f000002",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32773458",
                "http://www.ncbi.nlm.nih.gov/pubmed/34377935",
                "http://www.ncbi.nlm.nih.gov/pubmed/26064214",
                "http://www.ncbi.nlm.nih.gov/pubmed/23788674",
                "http://www.ncbi.nlm.nih.gov/pubmed/19755657",
                "http://www.ncbi.nlm.nih.gov/pubmed/28921583",
                "http://www.ncbi.nlm.nih.gov/pubmed/23539450",
                "http://www.ncbi.nlm.nih.gov/pubmed/37352389",
                "http://www.ncbi.nlm.nih.gov/pubmed/23794399",
                "http://www.ncbi.nlm.nih.gov/pubmed/25280443"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32773458",
                    "offsetInBeginSection": 934,
                    "offsetInEndSection": 1337,
                    "text": "Smoking was strongly associated with the risk of CRC, characterized by high CpG island methylator phenotype (RR 1.42; 95% CI 1.20-1.67; number of studies [n] = 4), BRAF mutation (RR 1.63; 95% CI 1.23-2.16; n = 4), or high microsatellite instability (RR 1.56; 95% CI 1.32-1.85; n = 8), but not characterized by KRAS (RR 1.04; 95% CI 0.90-1.20; n = 5) or TP53 (RR 1.13; 95% CI 0.99-1.29; n = 5) mutations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34377935",
                    "offsetInBeginSection": 745,
                    "offsetInEndSection": 964,
                    "text": "Heavier smokers had particularly higher risk of CRC subtypes that were CIMP positive and MSI high in combination, suggesting that smoking may be involved in the development of colorectal tumors via the serrated pathway.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26064214",
                    "offsetInBeginSection": 825,
                    "offsetInEndSection": 1108,
                    "text": "Smoking showed a significantly positive correlation with P53 mutation (exons 4 to 8), BRAF (codon 600) mutation, MSI positivity, and CIMP positivity, with ORs of 1.25 (95% CI: 1.07-1.45), 1.41 (95% CI: 1.18-1.68), 1.28 (95% CI: 1.12-1.47), and 1.23 (95% CI: 1.01-1.50), respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23788674",
                    "offsetInBeginSection": 727,
                    "offsetInEndSection": 1096,
                    "text": "Compared with current smoking, 10-19, 20-39, and 40 years of smoking cessation were associated with a lower risk of CIMP-high colorectal cancer, with multivariate hazard ratios (95% confidence intervals) of 0.53 (0.29, 0.95), 0.52 (0.32, 0.85), and 0.50 (0.27, 0.94), respectively (Ptrend = 0.001), but not with the risk of CIMP-low/CIMP-negative cancer (Ptrend = 0.25)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19755657",
                    "offsetInBeginSection": 1413,
                    "offsetInEndSection": 1512,
                    "text": "We found associations between cigarette smoking and increased risks of rectal cancer and MSI-H CRC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34377935",
                    "offsetInBeginSection": 645,
                    "offsetInEndSection": 744,
                    "text": "Smoking was associated with differential risk of CRC subtypes defined by molecular characteristics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28921583",
                    "offsetInBeginSection": 1367,
                    "offsetInEndSection": 1529,
                    "text": "Cigarette smoking was associated with lower overall survival, with suggestive evidence of worse survival for BRAF mutated CRC, but not with CRC-specific survival.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23539450",
                    "offsetInBeginSection": 1283,
                    "offsetInEndSection": 1549,
                    "text": "Risk factors for CIMP-high-serrated lesions included Caucasian race, current smoking status, and a history of polyps, whereas for serrated lesions with mutant BRAF, the significant risk factors were male sex, current smoking status, obesity, and a history of polyps.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37352389",
                    "offsetInBeginSection": 1515,
                    "offsetInEndSection": 1686,
                    "text": "This study is the first to demonstrate that smokers have an approximately 2-fold higher risk of KRAS wild-type colorectal cancer than never smokers in an Asian population.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23794399",
                    "offsetInBeginSection": 887,
                    "offsetInEndSection": 1157,
                    "text": "SNP associations observed for colon cancer were: VEGFA rs2010963 with CIMP+ colon tumors; FLT1 rs4771249 and rs7987649 with TP53; FLT1 rs3751397, rs7337610, rs7987649, and rs9513008 and KDR rs10020464, rs11941492, and rs12498529 with MSI+ and CIMP+/KRAS2-mutated tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What molecular subtypes of colon cancer are associated to smoking?",
            "type": "list",
            "id": "660998d1fdcbea915f000013",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What channel is targeted by VX-548?",
            "type": "factoid",
            "id": "65cfd02e1930410b1300001c",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32587855",
                "http://www.ncbi.nlm.nih.gov/pubmed/33570005",
                "http://www.ncbi.nlm.nih.gov/pubmed/32454052",
                "http://www.ncbi.nlm.nih.gov/pubmed/36625039",
                "http://www.ncbi.nlm.nih.gov/pubmed/28976890",
                "http://www.ncbi.nlm.nih.gov/pubmed/35850516",
                "http://www.ncbi.nlm.nih.gov/pubmed/36740450",
                "http://www.ncbi.nlm.nih.gov/pubmed/33476770",
                "http://www.ncbi.nlm.nih.gov/pubmed/25470007",
                "http://www.ncbi.nlm.nih.gov/pubmed/30113005"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32587855",
                    "offsetInBeginSection": 431,
                    "offsetInEndSection": 604,
                    "text": "Mitophagy, a selective autophagy of mitochondria, can efficiently degrade, remove and recycle the malfunctioning or damaged mitochondria, and is crucial for quality control.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33570005",
                    "offsetInBeginSection": 243,
                    "offsetInEndSection": 424,
                    "text": "Selective autophagic clearance of flawed mitochondria, a process termed mitophagy, is one of the most prominent mechanisms through which cells maintain a healthy mitochondrial pool.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32454052",
                    "offsetInBeginSection": 197,
                    "offsetInEndSection": 323,
                    "text": "Selective autophagy of mitochondria, id est mitophagy, is one of the cellular mechanisms controlling mitochondria homeostasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36625039",
                    "offsetInBeginSection": 163,
                    "offsetInEndSection": 282,
                    "text": "Mitophagy is a mechanism by which cells selectively wrap and degrade damaged mitochondria to maintain cell homeostasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28976890",
                    "offsetInBeginSection": 464,
                    "offsetInEndSection": 568,
                    "text": "One critical level of mitochondrial quality control is the removal of damaged mitochondria by mitophagy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35850516",
                    "offsetInBeginSection": 615,
                    "offsetInEndSection": 778,
                    "text": "Mitophagy and mitochondrial-specific autophagy play an important role in maintenance of neuronal health through the removal of dysfunctional and aged mitochondria.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36740450",
                    "offsetInBeginSection": 1664,
                    "offsetInEndSection": 1740,
                    "text": "Colocalization of mitochondria and lysosomes indirectly indicated mitophagy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33476770",
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 493,
                    "text": "As a part of mitochondrial quality control, the aged and damaged mitochondria are removed through a selective mode of autophagy called mitophagy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470007",
                    "offsetInBeginSection": 706,
                    "offsetInEndSection": 947,
                    "text": "This unique sensing property was successfully applied to the ratiometric fluorescence imaging of autolysosome formation in selective mitochondrial autophagy (mitophagy), which highlights the utility of this novel probe in autophagy research.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30113005",
                    "offsetInBeginSection": 283,
                    "offsetInEndSection": 445,
                    "text": "Mitochondria and mitochondrial autophagy play a vital role in cellular health and failure of these pathways can have a devastating effect on cellular homeostasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What part of the cell is mitophagy associated with?",
            "type": "factoid",
            "id": "660877c8fdcbea915f000008",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36262685",
                "http://www.ncbi.nlm.nih.gov/pubmed/34729291",
                "http://www.ncbi.nlm.nih.gov/pubmed/37218872",
                "http://www.ncbi.nlm.nih.gov/pubmed/12322966",
                "http://www.ncbi.nlm.nih.gov/pubmed/9689535",
                "http://www.ncbi.nlm.nih.gov/pubmed/12356284",
                "http://www.ncbi.nlm.nih.gov/pubmed/22180307",
                "http://www.ncbi.nlm.nih.gov/pubmed/12744155",
                "http://www.ncbi.nlm.nih.gov/pubmed/20535531",
                "http://www.ncbi.nlm.nih.gov/pubmed/9685941"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262685",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "text": "Micro-coring technology (MCT) removes cores of skin without formation of scars, thereby tightening skin and reducing skin wrinkling.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262685",
                    "offsetInBeginSection": 133,
                    "offsetInEndSection": 279,
                    "text": "The purpose of this study was to evaluate the safety and efficacy of MCT with the dermal micro-coring device for the treatment of facial wrinkles.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34729291",
                    "offsetInBeginSection": 119,
                    "offsetInEndSection": 231,
                    "text": "Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34729291",
                    "offsetInBeginSection": 650,
                    "offsetInEndSection": 748,
                    "text": "MCT treatment of human skin resulted in scarless skin removal that was well tolerated by patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218872",
                    "offsetInBeginSection": 298,
                    "offsetInEndSection": 438,
                    "text": "Microcoring technology has recently been developed to treat pores and serve as a leading primary treatment option to address these concerns.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12322966",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "text": "A system which consists of chitosan (CS) microcores entrapped within enteric polymer is investigated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218872",
                    "offsetInBeginSection": 987,
                    "offsetInEndSection": 1105,
                    "text": "Rotational fractional resection is a new concept that produces measurable permanent results for enlarged pore removal.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9689535",
                    "offsetInBeginSection": 218,
                    "offsetInEndSection": 464,
                    "text": "To address this limitation, a new microparticulate CS controlled release system, consisting of hydrophilic CS microcores entrapped in a hydrophobic cellulosic polymer, such as cellulose acetate butyrate (CAB) or ethyl cellulose (EC) was proposed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12356284",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "text": "In this work, a new microsphere delivery system comprising calcium alginate microcores surrounded by a biodegradable poly-DL-lactide-poly(ethylene glycol) (PELA) coat was designed to improve the loading efficiency and stability of peptide drugs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22180307",
                    "offsetInBeginSection": 653,
                    "offsetInEndSection": 1020,
                    "text": "Technical issues related to maximizing the diagnostic yield (e.g., rapid on-site cytopathological evaluation, needle diameter, microcore isolation for histopathological examination, and adequate number of needle passes) are discussed and recommendations are made for various settings, including solid and cystic pancreatic lesions, submucosal tumors, and lymph nodes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is Microcoring used for",
            "type": "factoid",
            "id": "65f37bb1c4010b4d7800000d",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11109315",
                "http://www.ncbi.nlm.nih.gov/pubmed/11244205",
                "http://www.ncbi.nlm.nih.gov/pubmed/12044582",
                "http://www.ncbi.nlm.nih.gov/pubmed/19091169",
                "http://www.ncbi.nlm.nih.gov/pubmed/31218948",
                "http://www.ncbi.nlm.nih.gov/pubmed/14727994",
                "http://www.ncbi.nlm.nih.gov/pubmed/15083596",
                "http://www.ncbi.nlm.nih.gov/pubmed/31384308",
                "http://www.ncbi.nlm.nih.gov/pubmed/9671773",
                "http://www.ncbi.nlm.nih.gov/pubmed/28578514"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11109315",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 776,
                    "text": "Mechanism for stroke reduction can be connected with nonlipid mechanism of statins action: modifying endothelial function and inflammatory responses, plaque stabilisation and inhibition of plaque progression and thrombus formation in the intracranial and extracranial carotid arteries.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11244205",
                    "offsetInBeginSection": 713,
                    "offsetInEndSection": 889,
                    "text": "These studies show a reduction in the risk of ischemic stroke, and although relative risk reduction is great, absolute risk reduction is low; the reasons for this are analyzed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12044582",
                    "offsetInBeginSection": 601,
                    "offsetInEndSection": 820,
                    "text": "In particular, the ability of statins to decrease the incidence of ischemic stroke highlights some of their non-cholesterol effects since serum cholesterol levels are poorly correlated with the risk for ischemic stroke.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19091169",
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 432,
                    "text": "Statins decrease the risk of cerebral infarction in patients with coronary disease, diabetes, hypertension, and hypercholesterolemia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31218948",
                    "offsetInBeginSection": 905,
                    "offsetInEndSection": 1042,
                    "text": "Similarly, in patients with a previous cerebrovascular event, there is a clear benefit of statins for the prevention of recurrent events.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31218948",
                    "offsetInBeginSection": 1301,
                    "offsetInEndSection": 1382,
                    "text": "Patients who experience a stroke while on statins should not discontinue statins.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31218948",
                    "offsetInBeginSection": 1661,
                    "offsetInEndSection": 1803,
                    "text": "Treatment with statins prevents ischemic stroke, especially in patients with high cardiovascular risk and established atherosclerotic disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14727994",
                    "offsetInBeginSection": 1726,
                    "offsetInEndSection": 1839,
                    "text": "In conclusion, HMG-CoA reductase inhibitors may have a role in primary prevention of stroke in patients with CAD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15083596",
                    "offsetInBeginSection": 330,
                    "offsetInEndSection": 454,
                    "text": "Lipid lowering with statins reduces the incidence of ischemic stroke without increasing the frequency of hemorrhagic stroke.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31384308",
                    "offsetInBeginSection": 556,
                    "offsetInEndSection": 857,
                    "text": "A total of 17 trials with 11,576 subjects with previous ischemic stroke, TIA, or ICH were included, in which statin therapy increased the risk of hemorrhagic stroke (risk ratio [RR], 1.42; 95% confidence interval [CI], 1.07-1.87), but reduced the risk of ischemic stroke (RR, 0.85; 95% CI, 0.75-0.95).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the association between statins and stroke?",
            "type": "summary",
            "id": "660d2a50fdcbea915f00003a",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32965323",
                "http://www.ncbi.nlm.nih.gov/pubmed/24152430",
                "http://www.ncbi.nlm.nih.gov/pubmed/28739131",
                "http://www.ncbi.nlm.nih.gov/pubmed/24355920",
                "http://www.ncbi.nlm.nih.gov/pubmed/11797144",
                "http://www.ncbi.nlm.nih.gov/pubmed/22466962",
                "http://www.ncbi.nlm.nih.gov/pubmed/21907570",
                "http://www.ncbi.nlm.nih.gov/pubmed/25430564",
                "http://www.ncbi.nlm.nih.gov/pubmed/24784702",
                "http://www.ncbi.nlm.nih.gov/pubmed/31377017"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32965323",
                    "offsetInBeginSection": 709,
                    "offsetInEndSection": 841,
                    "text": "In all doses, amifostine prevented the development of mechanical hyperalgesia and thermal allodynia induced by oxaliplatin (P<0.05).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32965323",
                    "offsetInBeginSection": 842,
                    "offsetInEndSection": 915,
                    "text": "Amifostine at the dose of 25 mg/kg provided the best protection (P<0.05).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32965323",
                    "offsetInBeginSection": 1161,
                    "offsetInEndSection": 1357,
                    "text": "In conclusion, amifostine reduced the nociception induced by oxaliplatin in mice, suggesting the possible use of amifostine for the management of oxaliplatin-induced peripheral sensory neuropathy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24152430",
                    "offsetInBeginSection": 1123,
                    "offsetInEndSection": 1219,
                    "text": "Rutin and quercetin (25-100 mg/kg, i.p.) were injected 30 min before each oxaliplatin injection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24152430",
                    "offsetInBeginSection": 2129,
                    "offsetInEndSection": 2240,
                    "text": "Oxaliplatin induced painful peripheral neuropathy in mice, an effect that was prevented by rutin and quercetin.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28739131",
                    "offsetInBeginSection": 764,
                    "offsetInEndSection": 875,
                    "text": "Ibudilast treatment prior to oxaliplatin prevented the development of tactile allodynia and memory impairments.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28739131",
                    "offsetInBeginSection": 1035,
                    "offsetInEndSection": 1171,
                    "text": "These results suggest that Ibudilast could be an effective treatment against oxaliplatin-induced neuropathies and cognitive impairments.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24355920",
                    "offsetInBeginSection": 1476,
                    "offsetInEndSection": 1590,
                    "text": "Our study suggests that mangafodipir can prevent and/or relieve oxaliplatin-induced neuropathy in cancer patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11797144",
                    "offsetInBeginSection": 1392,
                    "offsetInEndSection": 1519,
                    "text": "These observations demonstrate that oxaliplatin-induced sensory neuropathy more than grade 1 may be prevented by carbamazepine.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24152430",
                    "offsetInBeginSection": 553,
                    "offsetInEndSection": 711,
                    "text": "The flavonoids rutin and quercetin have been described as cell-protecting agents because of their antioxidant, antinociceptive, and anti-inflammatory actions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the most effective drug for oxaliplatin-induced neuropathy?",
            "type": "factoid",
            "id": "66099926fdcbea915f000016",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38051359"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38051359",
                    "offsetInBeginSection": 1479,
                    "offsetInEndSection": 1693,
                    "text": "The WW strategy in locally advanced rectal cancer offers similar oncological outcomes with respect to the surgical group and excellent results in quality of life and cost outcomes, especially for low rectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is watch-and-wait policy after neoadjuvant therapy a cost-effective policy for locally advanced rectal cancer patients?",
            "type": "yesno",
            "id": "65f778dbc4010b4d78000035",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20235893",
                "http://www.ncbi.nlm.nih.gov/pubmed/22538970",
                "http://www.ncbi.nlm.nih.gov/pubmed/20086106",
                "http://www.ncbi.nlm.nih.gov/pubmed/20228593",
                "http://www.ncbi.nlm.nih.gov/pubmed/33294846",
                "http://www.ncbi.nlm.nih.gov/pubmed/20846366",
                "http://www.ncbi.nlm.nih.gov/pubmed/20400343",
                "http://www.ncbi.nlm.nih.gov/pubmed/27522645",
                "http://www.ncbi.nlm.nih.gov/pubmed/37962456",
                "http://www.ncbi.nlm.nih.gov/pubmed/31701193"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20235893",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "Many women with endometriosis experience significant delay between the onset of symptoms and definitive diagnosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22538970",
                    "offsetInBeginSection": 91,
                    "offsetInEndSection": 204,
                    "text": "Patients commonly present with pelvic pain or infertility, although the range of clinical symptoms varies widely.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22538970",
                    "offsetInBeginSection": 205,
                    "offsetInEndSection": 322,
                    "text": "Affected women may be asymptomatic or experience mild, moderate, or severe pain that fluctuates with hormonal cycles.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20086106",
                    "offsetInBeginSection": 729,
                    "offsetInEndSection": 945,
                    "text": "The most common symptoms were pelvic pain followed by gastrointestinal symptoms, palpable mass, abdominal distension, vaginal bleeding, and newly developed or exacerbated dysmenorrhea (18.1%) and dyspareunia (13.6%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20086106",
                    "offsetInBeginSection": 1614,
                    "offsetInEndSection": 1704,
                    "text": "Dyspareunia and dysmenorrhea were more frequently detected in patients with endometriosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20228593",
                    "offsetInBeginSection": 69,
                    "offsetInEndSection": 153,
                    "text": "The symptoms and signs of ureteral endometriosis mimic those of ureteral malignancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33294846",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 262,
                    "text": "While the most common symptom associated with endometriosis is pelvic pain, the systemic manifestations of the disease and the accompanying adverse psychological, emotional, social, familial, sexual, educational and workplace effects are increasingly recognized.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20846366",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "text": "Endometriosis is a benign condition affecting females of reproductive age.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20400343",
                    "offsetInBeginSection": 864,
                    "offsetInEndSection": 964,
                    "text": "The main clinical finding emerging from this analysis suggests that pelvic pain is the main symptom.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27522645",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "Pain is the central symptom in endometriosis and often persists despite treatment of the disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What symptoms can be expected in women suffering from endometriosis?",
            "type": "list",
            "id": "660bbc09fdcbea915f00002a",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37880106",
                "http://www.ncbi.nlm.nih.gov/pubmed/36049114",
                "http://www.ncbi.nlm.nih.gov/pubmed/37747577",
                "http://www.ncbi.nlm.nih.gov/pubmed/35015342",
                "http://www.ncbi.nlm.nih.gov/pubmed/34237321",
                "http://www.ncbi.nlm.nih.gov/pubmed/37174697",
                "http://www.ncbi.nlm.nih.gov/pubmed/32977446",
                "http://www.ncbi.nlm.nih.gov/pubmed/32425074",
                "http://www.ncbi.nlm.nih.gov/pubmed/32916794",
                "http://www.ncbi.nlm.nih.gov/pubmed/35821852"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37880106",
                    "offsetInBeginSection": 776,
                    "offsetInEndSection": 1009,
                    "text": "In preclinical CVD models, senolytics appear to improve heart failure, ischemic heart disease, valvular heart disease, atherosclerosis, aortic aneurysm, vascular dysfunction, dialysis arteriovenous fistula patency, and pre-eclampsia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37880106",
                    "offsetInBeginSection": 185,
                    "offsetInEndSection": 437,
                    "text": "In recent years, therapies targeting senescent cells (senotherapies), particularly senolytics that selectively eliminate senescent cells, have been developed and show promise for treating geriatric syndromes and age-associated diseases, including CVDs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36049114",
                    "offsetInBeginSection": 1036,
                    "offsetInEndSection": 1241,
                    "text": "Therefore, we additionally attempt to clarify the current state of this field with a focus on cardiac senescence and discuss the potential of implementing senolytics as a treatment option in heart disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37747577",
                    "offsetInBeginSection": 303,
                    "offsetInEndSection": 479,
                    "text": "In recent years, the use and study of senolytics increased, representing a promising field for finding accessible and safe therapies for cardiovascular disease (CVD) treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35015342",
                    "offsetInBeginSection": 966,
                    "offsetInEndSection": 1139,
                    "text": "In this review, we discuss the role of senescent cells within the cardiovascular system and highlight the contribution of senescence cells to common cardiovascular diseases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34237321",
                    "offsetInBeginSection": 784,
                    "offsetInEndSection": 969,
                    "text": "In this review, we discuss the evidence demonstrating that senescence contributes to cardiovascular disease, with a particular focus on studies that indicate the promise of senotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37174697",
                    "offsetInBeginSection": 276,
                    "offsetInEndSection": 498,
                    "text": "Therapies targeting senescent cells, especially senolytic drugs that selectively induce senescent cell removal, have been shown to delay, prevent, alleviate, or treat multiple age-associated diseases in preclinical models.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32977446",
                    "offsetInBeginSection": 634,
                    "offsetInEndSection": 756,
                    "text": "Senescence-based therapeutic strategies are currently being pursued to treat and prevent CVD in humans in the near-future.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35015342",
                    "offsetInBeginSection": 1140,
                    "offsetInEndSection": 1361,
                    "text": "We discuss the emerging role for senolytics in cardiovascular disease management while highlighting important aspects of senescence biology which must be clarified before the potential of senolytics can be fully realized.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32425074",
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 527,
                    "text": "Major efforts are underway to develop drugs that selectively eliminate senescent cells (senolytics) or alter the SASP (senomorphics) to treat age-related diseases in humans.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Are senolytics used to treat cardiovascular disease?",
            "type": "yesno",
            "id": "66088ddbfdcbea915f00000d",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29098867",
                "http://www.ncbi.nlm.nih.gov/pubmed/26938945",
                "http://www.ncbi.nlm.nih.gov/pubmed/30553524",
                "http://www.ncbi.nlm.nih.gov/pubmed/28009435",
                "http://www.ncbi.nlm.nih.gov/pubmed/27412791",
                "http://www.ncbi.nlm.nih.gov/pubmed/31930187",
                "http://www.ncbi.nlm.nih.gov/pubmed/35787480",
                "http://www.ncbi.nlm.nih.gov/pubmed/35909271",
                "http://www.ncbi.nlm.nih.gov/pubmed/30180286",
                "http://www.ncbi.nlm.nih.gov/pubmed/31294429"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29098867",
                    "offsetInBeginSection": 172,
                    "offsetInEndSection": 338,
                    "text": "Mirvetuximab soravtansine is a novel antibody-drug conjugate that targets folate receptor-, a validated molecular target for therapeutic intervention in this disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26938945",
                    "offsetInBeginSection": 722,
                    "offsetInEndSection": 873,
                    "text": "deBouganin, a deimmunized plant toxin that inhibits protein synthesis, was conjugated to trastuzumab and compared with T-DM1 both in vitro and in vivo.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26938945",
                    "offsetInBeginSection": 874,
                    "offsetInEndSection": 1018,
                    "text": "The trastuzumab-deBouganin conjugate (T-deB) demonstrated greater potency in vitro against most cells lines with high levels of Her2 expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26938945",
                    "offsetInBeginSection": 1032,
                    "offsetInEndSection": 1160,
                    "text": "T-deB, unlike T-DM1, was unaffected by inhibitors of multidrug resistance, Bcl-2-mediated resistance, or Her2-Her3 dimerization.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26938945",
                    "offsetInBeginSection": 1305,
                    "offsetInEndSection": 1444,
                    "text": "Overall, the results demonstrate the potency and efficacy of deBouganin and emphasize the importance of using payloads with different MOAs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30553524",
                    "offsetInBeginSection": 80,
                    "offsetInEndSection": 186,
                    "text": "This payload introduces a novel mode of action into oncology therapy, the inhibition of RNA Polymerase II.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28009435",
                    "offsetInBeginSection": 1334,
                    "offsetInEndSection": 1573,
                    "text": "The findings support the proposed MOA: initial depletion of total B cells by antibody-mediated opsonization, followed by preferential, sustained depletion of proliferating B cells by the auristatin conjugate due to its anti-mitotic action.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27412791",
                    "offsetInBeginSection": 1251,
                    "offsetInEndSection": 1394,
                    "text": "Moreover, these ADCs were shown to promote altered splicing products in N87 cells in vitro, consistent with their putative mechanism of action.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31930187",
                    "offsetInBeginSection": 523,
                    "offsetInEndSection": 692,
                    "text": "The dual-drug ADC showed selective and potent cytotoxicity against HER2-expressing cell lines and exhibited dual mechanisms of action consistent with the attached drugs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30553524",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 250,
                    "text": "The high potency of the toxin leads to highly efficacious ADCs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the mechanism of action of Mirvetuximab Soravtansine?",
            "type": "summary",
            "id": "65cf6c301930410b13000008",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27812666",
                "http://www.ncbi.nlm.nih.gov/pubmed/25830998",
                "http://www.ncbi.nlm.nih.gov/pubmed/11980610",
                "http://www.ncbi.nlm.nih.gov/pubmed/31490924",
                "http://www.ncbi.nlm.nih.gov/pubmed/25501172",
                "http://www.ncbi.nlm.nih.gov/pubmed/27230435",
                "http://www.ncbi.nlm.nih.gov/pubmed/28377149",
                "http://www.ncbi.nlm.nih.gov/pubmed/29050834",
                "http://www.ncbi.nlm.nih.gov/pubmed/17114770",
                "http://www.ncbi.nlm.nih.gov/pubmed/23168052"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27812666",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 79,
                    "text": "Brazilian spotted fever (BSF) is caused by the bacterium Rickettsia rickettsii.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25830998",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "text": "Brazilian spotted fever is an acute febrile infectious disease caused by Rickettsia rickettsii, transmitted by tick bite.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11980610",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 56,
                    "text": "Brazilian spotted fever, caused by Rickettsia rickettsii",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31490924",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 220,
                    "text": "Brazilian spotted fever (BSF), caused by the bacterium Rickettsia rickettsii, has been associated with the transmission by the tick Amblyomma sculptum, and one of its main hosts, the capybara (Hydrochoerus hydrochaeris).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25501172",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "text": "Amblyomma aureolatum (Pallas) is the main vector of the bacterium Rickettsia rickettsii, the etiological agent of Brazilian spotted fever.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27230435",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "text": "The hard tick Amblyomma aureolatum (Pallas) is a vector of the bacterium Rickettsia rickettsii, the etiologic agent of Brazilian spotted fever (BSF) in parts of Brazil.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28377149",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "text": "Brazilian spotted fever (BSF) is an endemic anthropozoonosis caused by Gram-negative bacteria (Rickettsia rickettsii) that is associated with the risk of human infection by ticks.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29050834",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "text": "Brazilian spotted fever (BSF) is a potentially lethal human disease caused by Rickettsia rickettsii transmitted by ticks, including Amblyomma sculptum.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17114770",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "Brazilian spotted fever (BSF) is a highly lethal disease caused by Rickettsia rickettsii.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23168052",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "text": "Brazilian spotted fever (BSF) caused by Rickettsia rickettsii is the most important rickettsiosis and the only reportable tick-borne disease in Brazil.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the cause of Brazilian spotted fever?",
            "type": "factoid",
            "id": "660c0486fdcbea915f00002d",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32657876",
                "http://www.ncbi.nlm.nih.gov/pubmed/29873679",
                "http://www.ncbi.nlm.nih.gov/pubmed/33836264",
                "http://www.ncbi.nlm.nih.gov/pubmed/24138831",
                "http://www.ncbi.nlm.nih.gov/pubmed/24390240",
                "http://www.ncbi.nlm.nih.gov/pubmed/33108877",
                "http://www.ncbi.nlm.nih.gov/pubmed/37966682",
                "http://www.ncbi.nlm.nih.gov/pubmed/26338525",
                "http://www.ncbi.nlm.nih.gov/pubmed/28068936",
                "http://www.ncbi.nlm.nih.gov/pubmed/35112975"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32657876",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Triplet chemotherapy (FOLFOXIRI) + bevacizumab regimen is indicated as first-line treatment of BRAF-mutated metastatic colorectal cancer (mCRC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29873679",
                    "offsetInBeginSection": 1909,
                    "offsetInEndSection": 2127,
                    "text": "FOLFOXIRI plus bevacizumab may be regarded as a preferred first-line treatment option for clinically selected patients with right-sided metastatic colorectal cancer irrespective of their RAS and BRAF mutational status.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33836264",
                    "offsetInBeginSection": 855,
                    "offsetInEndSection": 1105,
                    "text": "The current standard therapies for first-line treatment of BRAF-mutated mCRC are chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24138831",
                    "offsetInBeginSection": 1571,
                    "offsetInEndSection": 1685,
                    "text": "FOLFOXIRI plus bevacizumab might be a reasonable option for the first-line treatment of BRAF mutant mCRC patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24390240",
                    "offsetInBeginSection": 615,
                    "offsetInEndSection": 783,
                    "text": "BRAF mutation carriers had worse ORR than non-carriers in mCRC patients with KRAS wild-type in first-line treatment whether adding anti-EGFR MoAb to chemotherapy or not",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33108877",
                    "offsetInBeginSection": 453,
                    "offsetInEndSection": 551,
                    "text": "For the first line treatment doublet or triplet chemotherapy plus antiangiogenic antibody is used.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37966682",
                    "offsetInBeginSection": 729,
                    "offsetInEndSection": 901,
                    "text": "Data indicate that patients with proficient MMR, RAS/BRAF wt mCRC are candidates for an anti-EGFR antibody plus doublet chemotherapy if they have a left-sided primary tumor",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338525",
                    "offsetInBeginSection": 2659,
                    "offsetInEndSection": 2874,
                    "text": "FOLFOXIRI plus bevacizumab is a feasible treatment option for those patients who meet the inclusion criteria of the present study, irrespective of baseline clinical characteristics and RAS or BRAF mutational status.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28068936",
                    "offsetInBeginSection": 1706,
                    "offsetInEndSection": 1850,
                    "text": "Patient selection according to RAS/PIK3CA/BRAF mutations could help select patients who will achieve a better response to bevacizumab treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35112975",
                    "offsetInBeginSection": 618,
                    "offsetInEndSection": 739,
                    "text": "As first-line therapy, 196 (54%) patients received bevacizumab and Anti-EGFR treatments in combination with chemotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the first-line treatment for BRAF mutated advanced colorectal cancer patients?",
            "type": "factoid",
            "id": "66099a25fdcbea915f00001e",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31890712",
                "http://www.ncbi.nlm.nih.gov/pubmed/27778245",
                "http://www.ncbi.nlm.nih.gov/pubmed/25747822",
                "http://www.ncbi.nlm.nih.gov/pubmed/1313237",
                "http://www.ncbi.nlm.nih.gov/pubmed/26839698",
                "http://www.ncbi.nlm.nih.gov/pubmed/18495029",
                "http://www.ncbi.nlm.nih.gov/pubmed/35145797",
                "http://www.ncbi.nlm.nih.gov/pubmed/8234222",
                "http://www.ncbi.nlm.nih.gov/pubmed/8771575",
                "http://www.ncbi.nlm.nih.gov/pubmed/14966256"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31890712",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "Nitrofurantoin-induced diffuse lung toxicity is well documented in the literature but is often misdiagnosed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31890712",
                    "offsetInBeginSection": 1068,
                    "offsetInEndSection": 1249,
                    "text": "Chronic pulmonary toxicity due to nitrofurantoin is rare and it occurs primarily in older women who have been prescribed relatively small doses of nitrofurantoin for UTI prevention.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27778245",
                    "offsetInBeginSection": 288,
                    "offsetInEndSection": 449,
                    "text": "We describe the case of a 73-year-old female who developed interstitial lung disease following chronic use of nitrofurantoin for a urinary tract infection (UTI).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25747822",
                    "offsetInBeginSection": 678,
                    "offsetInEndSection": 826,
                    "text": "Using clinical judgment and the algorithm of Naranjo, it was determined that nitrofurantoin use was the probable cause of the patient's lung injury.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31890712",
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 264,
                    "text": "We describe an 82-year-old female medicated with nitrofurantoin for the previous 2 years who was admitted for dyspnoea, dry cough and fatigue for 4 months.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1313237",
                    "offsetInBeginSection": 1332,
                    "offsetInEndSection": 1477,
                    "text": "The results of the present study suggest that nitrofurantoin can damage the lungs of rats, probably through oxidative stress-mediated mechanisms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26839698",
                    "offsetInBeginSection": 195,
                    "offsetInEndSection": 274,
                    "text": "the patient was diagnosed with nitrofurantoin-induced acute pulmonary toxicity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18495029",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 57,
                    "text": "Nitrofurantoin-induced pulmonary fibrosis: a case report.",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18495029",
                    "offsetInBeginSection": 1272,
                    "offsetInEndSection": 1354,
                    "text": "This case shows that the use of nitrofurantoin may cause severe pulmonary disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18495029",
                    "offsetInBeginSection": 1355,
                    "offsetInEndSection": 1461,
                    "text": "Patients with long-term use of nitrofurantoin should be monitored regularly for adverse pulmonary effects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can Nitrofurantoin cause Lung Injury?",
            "type": "yesno",
            "id": "65cfcf201930410b1300001b",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21092644",
                "http://www.ncbi.nlm.nih.gov/pubmed/28493373",
                "http://www.ncbi.nlm.nih.gov/pubmed/26666891",
                "http://www.ncbi.nlm.nih.gov/pubmed/20617149",
                "http://www.ncbi.nlm.nih.gov/pubmed/27148590",
                "http://www.ncbi.nlm.nih.gov/pubmed/27662471",
                "http://www.ncbi.nlm.nih.gov/pubmed/21823217",
                "http://www.ncbi.nlm.nih.gov/pubmed/22286171",
                "http://www.ncbi.nlm.nih.gov/pubmed/22683325",
                "http://www.ncbi.nlm.nih.gov/pubmed/23906401"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21092644",
                    "offsetInBeginSection": 1237,
                    "offsetInEndSection": 1294,
                    "text": "RCM may result from various local and systemic disorders.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493373",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Restrictive cardiomyopathy (RCM) is a rare heart disease characterized by diastolic dysfunction and atrial enlargement.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26666891",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 289,
                    "text": "Familial forms are mainly caused by mutations in sarcomere proteins and demonstrate a common genetic etiology with other inherited cardiomyopathies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20617149",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Mutations in sarcomeric proteins have recently been established as heritable causes of Restrictive Cardiomyopathy (RCM).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27148590",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "text": "Restrictive cardiomyopathy (RCM) is a rare cause of heart muscle disease with the highest mortality rate among cardiomyopathy types.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27662471",
                    "offsetInBeginSection": 1335,
                    "offsetInEndSection": 1480,
                    "text": "Mutations of genes encoding sarcomeric, cytoskeletal, and Z-line-associated proteins appear to have a predominant role in the development of RCM.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21823217",
                    "offsetInBeginSection": 1258,
                    "offsetInEndSection": 1367,
                    "text": "This is the first report of mutations in TPM1, MYL3, and MYL2 associated with primary, non-hypertrophied RCM.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22286171",
                    "offsetInBeginSection": 701,
                    "offsetInEndSection": 846,
                    "text": "Two nonsense and 13 missense MYPN variants were identified in subjects with DCM, HCM and RCM with the average cardiomyopathy prevalence of 1.66%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22683325",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "Restrictive cardiomyopathy (RCM) has been linked to mutations in the thin filament regulatory protein cardiac troponin I (cTnI).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23906401",
                    "offsetInBeginSection": 2034,
                    "offsetInEndSection": 2199,
                    "text": "Three heterozygous mutations including two in TNNI3 and one in TNNT2 gene are identified in the three RCMs respectively, which are considered as causative mutations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "List the causes of Restrictive cardiomyopathy (RCM)",
            "type": "list",
            "id": "65f1d9f8c4010b4d78000006",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36708320",
                "http://www.ncbi.nlm.nih.gov/pubmed/38020600",
                "http://www.ncbi.nlm.nih.gov/pubmed/36444905",
                "http://www.ncbi.nlm.nih.gov/pubmed/30656180",
                "http://www.ncbi.nlm.nih.gov/pubmed/37691319",
                "http://www.ncbi.nlm.nih.gov/pubmed/33068037",
                "http://www.ncbi.nlm.nih.gov/pubmed/37219716",
                "http://www.ncbi.nlm.nih.gov/pubmed/38043492",
                "http://www.ncbi.nlm.nih.gov/pubmed/34845147"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36708320",
                    "offsetInBeginSection": 468,
                    "offsetInEndSection": 681,
                    "text": "Omaveloxolone, a nuclear factor erythroid 2-related factor 2 (Nrf2) activator, is currently under review by the Food and Drug Administration (FDA) and has the potential to be the first approved treatment for FRDA.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38020600",
                    "offsetInBeginSection": 352,
                    "offsetInEndSection": 491,
                    "text": "Omaveloxolone has been recently approved as the first pharmacological treatment for FRDA in adults and adolescents aged 16 years and older.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36708320",
                    "offsetInBeginSection": 831,
                    "offsetInEndSection": 977,
                    "text": "The present perspective suggests that omaveloxolone is a rational and efficacious therapy that is possibly disease modifying in treatment of FRDA.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36444905",
                    "offsetInBeginSection": 182,
                    "offsetInEndSection": 369,
                    "text": "MOXIe part 2, a randomized double-blind placebo-controlled trial, showed omaveloxolone significantly improved modified Friedreich's Ataxia Rating Scale (mFARS) scores relative to placebo.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36444905",
                    "offsetInBeginSection": 1467,
                    "offsetInEndSection": 1628,
                    "text": "These results support the positive results of MOXIe part 2 and indicate a persistent benefit of omaveloxolone treatment on disease course in Friedreich's ataxia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30656180",
                    "offsetInBeginSection": 1144,
                    "offsetInEndSection": 1284,
                    "text": "Treatment of Friedreich ataxia patients with omaveloxolone at the optimal dose level of 160 mg/day appears to improve neurological function.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37691319",
                    "offsetInBeginSection": 847,
                    "offsetInEndSection": 1000,
                    "text": "Data from the MOXIe extension show that omaveloxolone provided persistent benefit over 3 years when compared to an untreated, matched cohort from FACOMS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37691319",
                    "offsetInBeginSection": 1424,
                    "offsetInEndSection": 1641,
                    "text": "These results suggest a meaningful slowing of Friedreich ataxia progression with omaveloxolone, and consequently detail how propensity-matched analysis may contribute to understanding of effects of therapeutic agents.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33068037",
                    "offsetInBeginSection": 1558,
                    "offsetInEndSection": 1699,
                    "text": "In the MOXIe trial, omaveloxolone significantly improved neurological function compared to placebo and was generally safe and well tolerated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37219716",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 309,
                    "text": "The exciting news about the US FDA approval of omaveloxolone as the first-ever drug to be approved for an inherited ataxia is welcome news for patients and families that deal with this devastating disease as well as for health care providers and investigators with an interest in this and other rare diseases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Omaveloxolone effective for Friedreich Ataxia?",
            "type": "yesno",
            "id": "65d12c451930410b13000032",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24163979",
                "http://www.ncbi.nlm.nih.gov/pubmed/7968159",
                "http://www.ncbi.nlm.nih.gov/pubmed/16801849",
                "http://www.ncbi.nlm.nih.gov/pubmed/8414562",
                "http://www.ncbi.nlm.nih.gov/pubmed/8009704",
                "http://www.ncbi.nlm.nih.gov/pubmed/1487663",
                "http://www.ncbi.nlm.nih.gov/pubmed/17331270",
                "http://www.ncbi.nlm.nih.gov/pubmed/9673636",
                "http://www.ncbi.nlm.nih.gov/pubmed/3656499",
                "http://www.ncbi.nlm.nih.gov/pubmed/651516"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163979",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "text": "Acute epiglottitis in children has almost vanished since the start of Hib vaccinations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7968159",
                    "offsetInBeginSection": 613,
                    "offsetInEndSection": 749,
                    "text": "Findings include a decline in disease prevalence in all geographic areas with demographic, etiologic, and management evolution all seen.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16801849",
                    "offsetInBeginSection": 319,
                    "offsetInEndSection": 403,
                    "text": "Over the past 27 years, the admission rate for acute epiglottitis declined ten fold.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8414562",
                    "offsetInBeginSection": 446,
                    "offsetInEndSection": 565,
                    "text": "Annual incidence in children, however, decreased from 3.47 cases per 100,000 in 1980 to 0.63 cases per 100,000 in 1990.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8414562",
                    "offsetInBeginSection": 566,
                    "offsetInEndSection": 668,
                    "text": "The ratio of annual incidence in children to that in adults decreased from 2.6 in 1980 to 0.4 in 1990.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8009704",
                    "offsetInBeginSection": 298,
                    "offsetInEndSection": 432,
                    "text": "The incidence of acute epiglottitis in children less than five years old was calculated to be 8.7/100,000 with minor annual variation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1487663",
                    "offsetInBeginSection": 657,
                    "offsetInEndSection": 765,
                    "text": "The incidence of acute epiglottitis in children was calculated at 3.2/100,000 with a minor annual variation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1487663",
                    "offsetInBeginSection": 766,
                    "offsetInEndSection": 1062,
                    "text": "As vaccination against Haemophilus influenzae type b becomes more common, the incidence will probably be markedly reduced, maybe even eradicated in children, but in adults the same reduction cannot be expected as the causative agent in this group is less frequently Haemophilus influenzae type b.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17331270",
                    "offsetInBeginSection": 549,
                    "offsetInEndSection": 653,
                    "text": "Acute epiglottitis admissions decreased markedly after 1992 but rose again in 2000, with a peak in 2002.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9673636",
                    "offsetInBeginSection": 317,
                    "offsetInEndSection": 428,
                    "text": "The incidence of epiglottitis increased significantly up until 1992. Since then there have been only two cases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Trends of acute epiglottitis in children.",
            "type": "summary",
            "id": "660d17dffdcbea915f000037",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7979195",
                "http://www.ncbi.nlm.nih.gov/pubmed/12385019",
                "http://www.ncbi.nlm.nih.gov/pubmed/20697958",
                "http://www.ncbi.nlm.nih.gov/pubmed/15131405",
                "http://www.ncbi.nlm.nih.gov/pubmed/9245993",
                "http://www.ncbi.nlm.nih.gov/pubmed/18715695",
                "http://www.ncbi.nlm.nih.gov/pubmed/32942876",
                "http://www.ncbi.nlm.nih.gov/pubmed/10432927",
                "http://www.ncbi.nlm.nih.gov/pubmed/15222003",
                "http://www.ncbi.nlm.nih.gov/pubmed/23938213"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7979195",
                    "offsetInBeginSection": 711,
                    "offsetInEndSection": 899,
                    "text": "A variety of extracolonic tumors may be encountered in HNPCC, including cancers of the endometrium, stomach, small bowel, urinary tract (renal pelvis and ureter), biliary system and ovary.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12385019",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "Endometrial carcinoma (EC) is the most common extracolonic tumor associated with hereditary nonpolyposis colorectal cancer (HNPCC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20697958",
                    "offsetInBeginSection": 934,
                    "offsetInEndSection": 1200,
                    "text": "By far, breast cancer (32 cases) was the most frequent extracolonic manifestation in women followed by endometrial (20 cases) and uterine cervix cancer (20 cases). For man, prostate (16 cases) and stomach (12 cases) cancer were the most frequent extracolonic tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15131405",
                    "offsetInBeginSection": 1409,
                    "offsetInEndSection": 1671,
                    "text": "The most frequent extra-colonic primary sites among the HNPCC families were: endometrium (26.5%) and breast (26.5%) (women), and stomach (35.1%) (men). Among the FCC families, the most common primary sites were: breast (27.8%) (women), and stomach (44.4%) (men).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9245993",
                    "offsetInBeginSection": 196,
                    "offsetInEndSection": 309,
                    "text": "Phenotypically, HNPCC is characterized by the early onset of colorectal cancers and various extracolonic cancers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18715695",
                    "offsetInBeginSection": 843,
                    "offsetInEndSection": 973,
                    "text": "Upper urinary tract tumors rank third (5%) after colon (63%) and endometrial (9%) cancer within the group of HNPCC related tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32942876",
                    "offsetInBeginSection": 347,
                    "offsetInEndSection": 677,
                    "text": "Lynch syndrome (hereditary nonpolypous colorectal cancer - HNPCC) is an autosomal dominant genetic condition that is associated with a high risk of colorectal cancer or other extracolonic tumors (adenocarcinoma of endometrium, stomach, ovarian carcinoma, carcinoma of urinary tract, small intestine, brain tumors and skin cancer).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10432927",
                    "offsetInBeginSection": 193,
                    "offsetInEndSection": 272,
                    "text": "Endometrial and ovarian cancers are common extracolonic tumors in this syndrome",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15222003",
                    "offsetInBeginSection": 1584,
                    "offsetInEndSection": 1753,
                    "text": "CRC and endometrial carcinoma were associated with a greater probability of detecting pathogenic mutations in mismatch repair genes, with MSH2 involvement predominating.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23938213",
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 385,
                    "text": "Patients inheriting this predisposition are susceptible to colorectal, endometrial and other extracolonic tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What non-colonic tumors are associated with Lynch syndrome?",
            "type": "list",
            "id": "6609997ffdcbea915f000019",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        }
    ]
}